[{"text": "PREMIUM Biofrontera Says Last Patient Completes 1-Year Follow-Up in Skin Cancer Treatment Study; Shares Jump MT Newswires Wed, Jan 8, 2025, 7:31 PM 1 min read Biofrontera (BFRI) said Wednesday that the last patient completed the one-year follow-up visit in a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2025-01-08T19:31:58", "sentiment": {"score": 0.051757813431322575, "confidence": 0.06502468138933182, "probabilities": {"positive": 0.06502468138933182, "negative": 0.013266867958009243, "neutral": 0.9217084646224976}}, "embedding": [-0.07535560429096222, -0.08527762442827225, -0.05420894920825958, -0.0724954754114151, 0.20681633055210114, -0.09736383706331253, -0.20282943546772003, 0.0948224663734436, 0.0049346135929226875, 0.01673184335231781, 0.08803439140319824, 0.18187150359153748, -0.06586670130491257, 0.054540637880563736, 0.028771840035915375, 0.00865001417696476, -0.06570921838283539, -0.1905544549226761, 0.108808733522892, 0.040160492062568665, -0.25982120633125305, 0.02519272081553936, 0.14305360615253448, 0.12357112020254135, 0.043441951274871826, 0.029167206957936287, -0.19455060362815857, -0.04361635446548462, -0.017188796773552895, 0.10688528418540955, 0.1529206782579422, -0.04425589740276337, 0.04106208682060242, -0.04327293485403061, -0.015562670305371284, -0.09625448286533356, -0.10771284997463226, 0.09496191143989563, -0.17984502017498016, 0.15687988698482513, -0.008859189227223396, -0.2015306055545807, -0.16138127446174622, 0.1607353687286377, 0.14026974141597748, -0.18568280339241028, -0.09470371156930923, -0.027790334075689316, 0.15559744834899902, 0.10850214958190918, -0.13023118674755096, -0.22105145454406738, -0.06722099334001541, -0.033427391201257706, -0.020470820367336273, 0.0666419267654419, -0.10529657453298569, -0.09826023876667023, -0.12317394465208054, -0.07538727670907974, -0.0008128982153721154, -0.20616815984249115, -0.06618470698595047, 0.02516115829348564, 0.12846344709396362, 0.008543194271624088, 0.10313507169485092, -0.10802502930164337, 0.10964789241552353, 0.05850059539079666, -0.045995742082595825, -0.03914552554488182, 0.016676094383001328, 0.11943545192480087, 0.009653928689658642, 0.20719793438911438, 0.17715682089328766, 0.11839383840560913, 0.19693854451179504, -0.16027814149856567, -0.03553915396332741, -0.08987344801425934, 0.15835046768188477, 0.06338442116975784, -0.06984777003526688, -0.132083460688591, -0.07997360080480576, -0.014877389185130596, -0.19506610929965973, -0.03469105064868927, 0.22812631726264954, 0.06883357465267181, -0.015850257128477097, 0.07353866100311279, -0.24027860164642334, -0.05964219197630882, -0.20096875727176666, -0.03245915099978447, -0.061550237238407135, -0.01006520539522171, -0.14395904541015625, -0.17431053519248962, -0.05030491575598717, 0.07430063933134079, -0.10620982944965363, -0.1301061511039734, -0.11848238855600357, 0.07173817604780197, -0.061600007116794586, 0.07927022874355316, 0.061183322221040726, 0.06372945755720139, 0.07742112874984741, -0.06673765927553177, -0.08306756615638733, 0.2243417501449585, -0.0951499417424202, -0.0035796205047518015, 0.2272954285144806, -0.01709212362766266, 0.07544149458408356, 0.010666481219232082, 0.10544946789741516, -0.1069508045911789, -0.01837560161948204, 0.01690457947552204, 0.1391722857952118, 1.1059307257241354e-32, 0.09827148914337158, 0.09162845462560654, 0.06947846710681915, -0.03985687717795372, -0.07802820950746536, 0.014172093942761421, 0.018138373270630836, -0.23933395743370056, -0.04554754123091698, -0.1284724324941635, -0.03873573616147041, 0.20582741498947144, -0.010600961744785309, 0.04111051559448242, -0.26929348707199097, -0.11116862297058105, 0.03001434914767742, 0.15310454368591309, 0.004976356867700815, -0.08675020188093185, 0.19134528934955597, -0.13112126290798187, -0.014367825351655483, -0.029741043224930763, -0.000880071020219475, 0.09792155772447586, 0.004732612986117601, 0.11735663563013077, 0.023798054084181786, 0.07328495383262634, -0.14497290551662445, 0.1408853828907013, -0.0377889908850193, -0.09282787144184113, -0.07349870353937149, 0.0761553943157196, 0.12460464239120483, -0.14370284974575043, 0.10703319311141968, -0.09868454188108444, 0.005508244037628174, 0.04404419660568237, 0.08946311473846436, -0.06367316842079163, -0.008787132799625397, -0.1097237691283226, -0.16263148188591003, -0.14381632208824158, 0.1035938635468483, -0.006849955767393112, -0.08719845861196518, -0.10654114186763763, -0.18936771154403687, 0.009330951608717442, -0.06912687420845032, -0.02429167367517948, -0.1870671659708023, -0.046934355050325394, 0.1179131418466568, 0.0700816661119461, 0.36426475644111633, 0.01646382547914982, -0.08496151864528656, -0.015153550542891026, -0.1967712938785553, 0.07802155613899231, 0.00994916632771492, -0.11097533255815506, -0.11223451793193817, 0.1372261345386505, 0.05095532909035683, 0.11714903265237808, 0.07377807796001434, -0.05824107304215431, 0.06350420415401459, -0.08994009345769882, 0.02750985138118267, 0.08319897949695587, -0.027028370648622513, 0.1800915151834488, 0.04804477095603943, -0.011481373570859432, -0.04818318411707878, 0.1399158090353012, 0.06396941095590591, 0.11300694942474365, 0.02791486866772175, 0.0038461857475340366, -0.12445639073848724, -0.07710468024015427, 0.03893314674496651, -0.05177047848701477, 0.09862436354160309, 0.17221912741661072, -0.051242828369140625, -1.4026678911367073e-32, -0.06582656502723694, 0.01019092183560133, 0.09888409823179245, -0.10223899036645889, 0.10993043333292007, -0.022576844319701195, -0.11542880535125732, 0.21689099073410034, 0.15615034103393555, 0.06796629726886749, 0.1514180451631546, 0.10976516455411911, -0.06935717910528183, -0.03938515856862068, -0.08712302148342133, 0.07100042700767517, 0.05489372834563255, -0.25833526253700256, -0.18824705481529236, -0.021588610485196114, -0.030052822083234787, 0.07221632450819016, -0.211956188082695, 0.025514962151646614, -0.03755439817905426, -0.08572283387184143, 0.1833430528640747, 0.16762617230415344, -0.014456248842179775, -0.26747140288352966, -0.05298560485243797, -0.04174252599477768, -0.19438436627388, 0.0008156984113156796, 0.06015380099415779, -0.02316397987306118, 0.06443800032138824, 0.007956555113196373, -0.09316065162420273, 0.13351958990097046, 0.16199037432670593, -0.13640573620796204, -0.17091748118400574, 0.04135078564286232, 0.1947290003299713, 0.11817160993814468, -0.11434642970561981, 0.0008339893538504839, 0.12920226156711578, 0.048842720687389374, -0.008325847797095776, 0.11077524721622467, 0.15514498949050903, -0.0022357457783073187, -0.02142246812582016, -0.09736932814121246, 0.08675798773765564, 0.09669577330350876, -0.042020440101623535, 0.025553422048687935, 0.09787163883447647, 0.040537286549806595, -0.1309642344713211, -0.10408507287502289, 0.07866629958152771, 0.15492422878742218, 0.12304428964853287, -0.1098911315202713, 0.07618381828069687, 0.07195188850164413, -0.04242497682571411, 0.01786443591117859, -0.26373398303985596, -0.21045252680778503, 0.06910188496112823, 0.08726663142442703, -0.04705660417675972, -0.13933321833610535, -0.05888475477695465, 0.016780827194452286, -0.08011902123689651, -0.11437593400478363, 0.10095113515853882, -0.03821733593940735, 0.12820185720920563, 0.07105652987957001, 0.03922371193766594, -0.04911065846681595, -0.12699836492538452, 0.04346005246043205, -0.04391602799296379, -0.1695278137922287, -0.14871889352798462, 0.04323913902044296, -0.05471799150109291, -1.0024165675304175e-07, 0.1612066626548767, 0.05234108492732048, 0.0553966760635376, -0.10220347344875336, 0.20467203855514526, 0.07350058108568192, -0.008571865037083626, 0.032104428857564926, 0.13836289942264557, 0.05187468230724335, -0.08007168024778366, 0.14857368171215057, 0.08861769735813141, -0.08317141234874725, -0.06854959577322006, 0.09456474334001541, 0.045631784945726395, 0.04320644214749336, -0.011537624523043633, -0.1652102917432785, -0.12371300905942917, 0.04005587473511696, 0.17055755853652954, -0.16119232773780823, 0.018837040290236473, 0.028575407341122627, 0.00538875674828887, 0.09765473008155823, -0.00014570816711056978, -0.07179190963506699, 0.03040911629796028, -0.02860925905406475, 0.0774279236793518, 0.005788806825876236, -0.012050507590174675, -0.05311419442296028, 0.13102984428405762, -0.02886739745736122, 0.07335665076971054, 0.12797535955905914, 0.13061173260211945, -0.01959978975355625, 0.0486748069524765, 0.10833993554115295, -0.07066211849451065, 0.017046183347702026, -0.10239467769861221, -0.15857915580272675, -0.017832327634096146, -0.1757911592721939, 0.08141366392374039, -0.12357090413570404, 0.039653658866882324, 0.011089911684393883, -0.1119796484708786, 0.051770325750112534, -0.023557770997285843, -0.04416399449110031, -0.005933353677392006, 0.1067155972123146, 0.18012526631355286, -0.31452062726020813, 0.044494111090898514, 0.14612816274166107], "changes": {"1wk": -15.254233521108176}}, {"text": "Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz\u00ae-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) Biofrontera Inc. Wed, Jan 8, 2025, 5:50 PM 5 min read In This Article: BFRI BFRIW Biofrontera Inc. Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024. Data from follow-up will be included in FDA submission, expected in Q3 2025. Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024. BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year 1 . WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC (ALA-BCC-CT013) was met with the last patient completing the 1 year follow-up visit in December of 2024. The double-blind, randomized, placebo-controlled, multi-center study evaluated safety and efficacy in 187 patients with one or more clinically and histologically confirmed superficial BCCs. They each received one\u00a0cycle of two PDT treatments (either Ameluz \u00ae -PDT or placebo-PDT) 1-2 weeks apart. Lesions that were not completely resolved after 3 months were retreated. The FDA has advised Biofrontera to submit the sNDA with one-year follow-up data. While 1-year data will support the FDA submission, the superficial BCC lesions will in total be followed up for five years. Long-term follow-up studies are often required by the FDA for dermatology product submissions, in particular for skin cancers, and they are important in trials enrolling sBCC patients due to the risk of local recurrence, or subsequent additional skin cancer development. \u201cWe were delighted with the highly statistically significant results for the primary and secondary endpoints that we communicated last year\u201d, stated Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. \u201cThe completion of the 1-year follow-up is a crucial milestone in our path to an FDA submission in 2025 and potentially expanding our label to the treatment of a cutaneous malignancy. It demonstrates our continued investment in PDT and supports our vision of partnering with the dermatology community to improve patient care\u201d he concluded. \u201cWe routinely use PDT in our institution for the treatment of actinic keratoses\u201d commented Dr Shane Chapman, Chair of the Department of Dermatology at Dartmouth Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth, and an investigator for ALA-BCC-CT013. \u201cWe were impressed with the results of the 12-week data and I look forward to being able to offer Ameluz-PDT as a treatment option for my patients with sBCC\u201d. Story Continues About Basal Cell Carcinoma BCC is the most common form of skin cancer and the most frequently occurring form of all cancers. In the U.S. alone, an estimated 3.6 million cases are diagnosed each year, a subset of which is superficial basal cell carcinoma. BCCs arise from abnormal, uncontrolled growth of basal cells at the bottom of the epidermis. They rarely spread beyond the original tumor site but, if untreated, can become locally invasive, grow wide and deep into the skin, and destroy skin, tissue and bone. 1 https:// www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/ About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz \u00ae with the RhodoLED \u00ae lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter . Forward-Looking Statements Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to the clinical development strategy for Ameluz \u00ae , ongoing clinical trials and the future impact of such trials on the market for Ameluz \u00ae , Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company\u2019s relationship with its licensors; the ability of the Company\u2019s licensors to fulfill their obligations to the Company in a timely manner; the Company\u2019s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company\u2019s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company\u2019s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz \u00ae in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company\u2019s expectations; the Company\u2019s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), which can be obtained on the SEC\u2019s website at www.sec.gov . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management\u2019s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact: Investor Relations Andrew Barwicki 1-516-662-9461 ir@bfri.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2025-01-08T17:50:00", "sentiment": {"score": 0.25981017760932446, "confidence": 0.2752147614955902, "probabilities": {"positive": 0.2752147614955902, "negative": 0.015404583886265755, "neutral": 0.7093806862831116}}, "embedding": [-0.09301403909921646, -0.05799272283911705, -0.06611384451389313, -0.04873671010136604, 0.0022929105907678604, -0.08249024301767349, -0.08599726110696793, 0.2955917418003082, 0.0799110010266304, 0.043132469058036804, 0.006250866688787937, -0.03534206748008728, 0.02488371543586254, 0.01596367359161377, 0.021573828533291817, 0.07086482644081116, 0.012845204211771488, -0.04365405812859535, 0.054236337542533875, 0.03679417818784714, -0.12990523874759674, -0.015220243483781815, 0.07272101193666458, 0.07009439915418625, -0.0725882351398468, -0.034369539469480515, -0.09397965669631958, -0.012899164110422134, -0.12504227459430695, -0.06928905844688416, 0.1254080981016159, 0.07645723968744278, -0.06626945734024048, -0.09016130119562149, 0.02402072213590145, -0.10723856091499329, -0.16393226385116577, 0.04212724417448044, -0.13540643453598022, 0.03817250207066536, -0.09821614623069763, -0.0325048454105854, -0.17708386480808258, 0.015064314007759094, 0.11128155142068863, -0.14086154103279114, -0.08410722017288208, 0.04308584704995155, 0.015067614614963531, 0.031096652150154114, -0.022962696850299835, -0.06021060794591904, -0.14314836263656616, 0.13543960452079773, -0.03800045698881149, -0.03800521790981293, -0.14127913117408752, 0.05070621147751808, 0.05257950723171234, 0.041688427329063416, -0.06497891992330551, -0.08676109462976456, -0.012819851748645306, -0.03721463680267334, 0.21301382780075073, 0.024201136082410812, -0.03528761863708496, -0.15403270721435547, 0.060808002948760986, 0.05170361325144768, 0.02738199755549431, -0.09702776372432709, 0.0600312277674675, 0.029579265043139458, -0.06895866245031357, 0.07396936416625977, 0.12121321260929108, 0.19236943125724792, 0.040301427245140076, -0.08051501959562302, 0.023367587476968765, 0.15174785256385803, 0.034838344901800156, -0.04153358191251755, -0.002977007068693638, -0.06783433258533478, -0.015403471887111664, 0.09966428577899933, -0.04417198523879051, 0.0826721340417862, 0.1869177520275116, 0.10904158651828766, -0.1425330489873886, 0.011099213734269142, -0.07569186389446259, -0.0774698331952095, -0.0008540814742445946, -0.013632237911224365, 0.0728902742266655, -0.03779183328151703, -0.058702703565359116, -0.12428661435842514, -0.15059345960617065, -0.012302438728511333, -0.11168843507766724, -0.08825099468231201, -0.010995225980877876, -0.05840205028653145, -0.010841215960681438, -0.049775831401348114, 0.032641008496284485, 0.014890631660819054, -0.007193560246378183, -0.04626290500164032, -0.04941888153553009, 0.09333859384059906, 0.017179910093545914, -0.021753504872322083, 0.15846046805381775, -0.14094537496566772, -0.0076078325510025024, -0.06559203565120697, 0.11782495677471161, -0.19800138473510742, -0.006804144009947777, -0.00394867267459631, 0.056347668170928955, 1.3608787730913873e-32, 0.02558698132634163, 0.07453186064958572, -0.019014231860637665, 0.04944204166531563, -0.0835777297616005, 0.07365749776363373, 0.015493855811655521, -0.09023001044988632, -0.102359339594841, -0.1197706013917923, 0.0067556481808424, 0.030809840187430382, 3.9319274947047234e-05, 0.07978489249944687, -0.09339790046215057, -0.01902862638235092, 0.00034186779521405697, -0.04396095871925354, -0.15539652109146118, -0.08831211924552917, 0.055412545800209045, 0.08538370579481125, -0.049137942492961884, -0.048424385488033295, -0.07431076467037201, 0.09643232822418213, -0.08404926210641861, 0.09815216809511185, -0.05193366855382919, 0.05484900623559952, -0.046997010707855225, 0.10967394709587097, -0.0031137254554778337, -0.012213739566504955, -0.09078308939933777, -0.011206097900867462, 0.06308876723051071, -0.12623485922813416, 0.029721517115831375, 0.008400230668485165, -0.019611740484833717, 0.09903065115213394, 0.02086317166686058, -0.06447605043649673, 0.09035126864910126, -0.012239363975822926, -0.0870271772146225, 0.012357821688055992, -0.027543429285287857, -0.026172086596488953, -0.036162979900836945, -0.00019522849470376968, 0.03413515165448189, 0.005262506194412708, -0.018125904724001884, 0.09018132090568542, -0.20420172810554504, -0.03779607638716698, 0.054647885262966156, 0.15983304381370544, 0.22033044695854187, 0.059640802443027496, -0.0748974084854126, 0.05005469173192978, -0.1298534870147705, 0.021655429154634476, 0.03801630437374115, 0.1011633649468422, -0.09946298599243164, 0.01810159906744957, 0.020046699792146683, 0.07104204595088959, 0.25709643959999084, 0.023533839732408524, 0.20847199857234955, 0.0005775913596153259, 0.2038612961769104, 0.25416478514671326, -0.1007336676120758, -0.04007158800959587, -0.026327792555093765, 0.11250214278697968, -0.04041652753949165, 0.019395144656300545, 0.059892311692237854, 0.0030942836310714483, 0.01209217868745327, -0.006077907048165798, -0.2311699092388153, 0.043965019285678864, 0.06709985435009003, -0.06271041929721832, 0.01802857592701912, 0.1995665431022644, -0.0989701971411705, -1.3531481344932045e-32, 0.029276344925165176, 0.046963468194007874, 0.053534477949142456, -0.12772506475448608, 0.0021672286093235016, 0.12532487511634827, 0.13791722059249878, -0.0025274399667978287, 0.06462342292070389, -0.12136927992105484, 0.019270755350589752, 0.030880823731422424, -0.03591631352901459, -0.106484055519104, -0.05396300554275513, -0.03416908532381058, -0.009575947187840939, -0.06468753516674042, -0.2931114137172699, -0.0074768983758986, 0.02657300978899002, 0.08448909968137741, -0.05956818535923958, -0.0748523622751236, -0.09738505631685257, 0.020373262465000153, 0.022978803142905235, 0.027306262403726578, 0.01218685507774353, -0.0708233118057251, -0.014498299919068813, 0.04912552237510681, -0.1654684692621231, -0.04618564248085022, 0.012538330629467964, -0.027608104050159454, 0.08306660503149033, -0.15221461653709412, -0.1060146614909172, 0.01450266968458891, 0.06994190812110901, 0.004667928442358971, -0.15205176174640656, -0.047682762145996094, 0.08033831417560577, 0.021477866917848587, -0.0456155464053154, -0.045450497418642044, 0.16948077082633972, 0.09773457050323486, -0.038609206676483154, -0.011912081390619278, 0.03830629959702492, 0.07684044539928436, 0.011361222714185715, -0.03731852397322655, 0.1072351485490799, -0.012094647623598576, -0.07657204568386078, 0.19085368514060974, 0.07385719567537308, 0.02090068906545639, 0.07837019860744476, -0.015852566808462143, 0.18640275299549103, 0.1922396570444107, 0.0694764107465744, -0.01492365263402462, 0.1529078185558319, 0.024312756955623627, -0.0694490447640419, 0.003875797614455223, -0.15667663514614105, -0.07898689806461334, 0.023992160335183144, 0.10336318612098694, -0.0002910979092121124, -0.12369990348815918, -0.08346370607614517, -0.06661660969257355, -0.03310006111860275, -0.10824835300445557, 0.006430105771869421, -0.002316567115485668, 0.1336575150489807, 0.13301971554756165, -0.025267312303185463, -0.12282859534025192, -0.05068064481019974, 0.04075852781534195, -0.03348255157470703, -0.052401527762413025, -0.004905087873339653, 0.12671944499015808, 0.07052431255578995, -1.0073966905110865e-07, 0.07404699921607971, -0.08077537268400192, 0.0467749685049057, -0.09897814691066742, 0.07057514041662216, -0.007841064594686031, 0.005490783601999283, -0.026793159544467926, 0.02125892974436283, 0.06619423627853394, -0.06117460876703262, 0.1109871119260788, -0.040405869483947754, -0.05485348403453827, -0.13552172482013702, 0.07546143978834152, 0.06137240678071976, -0.04035366326570511, -0.017863422632217407, -0.08049263060092926, -0.1630956530570984, -0.10577989369630814, 0.08811025321483612, -0.08906145393848419, 0.019502919167280197, -0.0347914956510067, 0.09568386524915695, 0.21057313680648804, -0.0022393357940018177, -0.04800892993807793, 0.09534932672977448, -0.06814383715391159, 0.07951999455690384, 0.010343489237129688, -0.007165990304201841, -0.08052130043506622, 0.01217136811465025, 0.04168090969324112, 0.0029005156829953194, 0.2368813157081604, 0.04807976633310318, -0.005585880018770695, 0.017416730523109436, 0.07557249814271927, 0.0016823727637529373, -0.05345156788825989, -0.14357784390449524, -0.006376909092068672, -0.0440516360104084, -0.05871959775686264, -0.024755064398050308, -0.07903344184160233, -0.05716615170240402, 0.003608779050409794, -0.10536745190620422, 0.013099421747028828, 0.03179403394460678, 0.03097006492316723, 0.10398498922586441, -0.014896014705300331, 0.05150972306728363, -0.15121106803417206, 0.08725091814994812, 0.1439628005027771], "changes": {"1wk": -15.254233521108176}}, {"text": "Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates Zacks Equity Research Thu, Nov 14, 2024, 3:10 AM 3 min read In This Article: BFRIW Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.81%. A quarter ago, it was expected that this company would post a loss of $1.19 per share when it actually produced a loss of $1.12, delivering a surprise of 5.88%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Biofrontera Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.01 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 18.15%. This compares to year-ago revenues of $8.9 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Biofrontera Inc. Shares have lost about 66% since the beginning of the year versus the S&P 500's gain of 25.5%. What's Next for Biofrontera Inc. While Biofrontera Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Biofrontera Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $14.21 million in revenues for the coming quarter and -$3.07 on $40.97 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Spero Therapeutics, Inc. (SPRO), has yet to report results for the quarter ended September 2024. The results are expected to be released on November 14. This company is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of -1450%. The consensus EPS estimate for the quarter has been revised 50% higher over the last 30 days to the current level. Spero Therapeutics, Inc.'s revenues are expected to be $23 million, down 9.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biofrontera Inc. (BFRI) : Free Stock Analysis Report Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-14T03:10:02", "sentiment": {"score": -0.7313123680651188, "confidence": 0.7800597548484802, "probabilities": {"positive": 0.048747386783361435, "negative": 0.7800597548484802, "neutral": 0.17119286954402924}}, "embedding": [-0.11035005748271942, -0.02658909745514393, -0.07681655138731003, 0.018605219200253487, 0.036055613309144974, -0.07056881487369537, -0.14053282141685486, 0.14535456895828247, 0.22925062477588654, 0.10282111167907715, -0.10235536098480225, 0.05537471920251846, -0.05759795010089874, -0.03264074772596359, -0.12896600365638733, -0.07815657556056976, -0.025838036090135574, -0.03399292379617691, -0.10775953531265259, 0.04654676839709282, -0.10349977016448975, 0.02854887582361698, 0.10416995733976364, 0.09499257802963257, 0.10568627715110779, 0.016511349007487297, -0.11964385956525803, 0.03988988324999809, -0.18030419945716858, -0.13907389342784882, 0.03452010452747345, 0.13648264110088348, 0.14056921005249023, -0.08147124946117401, -0.1044543981552124, -0.03281771391630173, -0.012821894139051437, 0.09170477092266083, 0.13084495067596436, -0.022092610597610474, -0.05981865152716637, 0.043883755803108215, -0.13666567206382751, -0.0066338470205664635, -0.01564250886440277, -0.11347557604312897, -0.02112552523612976, 0.021799340844154358, 0.0851203203201294, 0.060670964419841766, -0.20974621176719666, -0.1128084808588028, 0.001803634688258171, 0.030210081487894058, -0.121381975710392, 0.05980522930622101, -0.002564915455877781, -0.13497492671012878, 0.05793926492333412, 0.0852268636226654, 0.04675573855638504, -0.02242303639650345, 0.05729334056377411, 0.04214809834957123, 0.24195203185081482, -0.008749470114707947, -0.0012339279055595398, 0.039403632283210754, -0.0933624729514122, 0.051440220326185226, 0.11973713338375092, -0.035109300166368484, -0.0897625982761383, 0.022418836131691933, -0.20209786295890808, 0.1273452788591385, 0.13555385172367096, 0.1610797792673111, 0.13486923277378082, -0.09183751046657562, 0.06298734247684479, -0.01841803640127182, -0.0649193823337555, -0.026650771498680115, 0.026426739990711212, -0.004600906744599342, 0.14399001002311707, 0.07776620984077454, 0.04094097018241882, 0.06479981541633606, -0.039249494671821594, -0.09301994740962982, 0.04587684944272041, -0.02082196995615959, 0.049376778304576874, 0.04235619306564331, -0.09039156883955002, -0.14202973246574402, 0.011912770569324493, 0.013759948313236237, 0.11032460629940033, 0.1140885204076767, -0.09527279436588287, -0.11229312419891357, -0.03586028516292572, -0.10332213342189789, 0.07761751860380173, 0.0331868901848793, 0.08204206824302673, 0.13122053444385529, -0.06699834764003754, 0.15360695123672485, -0.1713249534368515, -0.05566420778632164, -0.06464914977550507, 0.06829730421304703, -0.03822293505072594, 0.08090845495462418, 0.1127079427242279, 0.06590427458286285, 0.04437023401260376, 0.12179669737815857, 0.042917534708976746, -0.04528236761689186, 0.02123446762561798, -0.0055169472470879555, -0.18782678246498108, 7.897202474274446e-33, 0.0983084887266159, 0.09726956486701965, -0.017427820712327957, -0.09811843931674957, -0.06106409430503845, -0.011922068893909454, -0.009646541438996792, -0.08120561391115189, -0.012926142662763596, -0.0767526775598526, -0.11482391506433487, 0.10809257626533508, -0.05454161763191223, -0.09964151680469513, 0.01923873834311962, -0.15308551490306854, -0.044936083257198334, 0.023887809365987778, 0.0009643472731113434, -0.07172563672065735, 0.04953065887093544, 0.008199308067560196, -0.03936947509646416, -0.0016833702102303505, 0.06465543806552887, 0.009288666769862175, -0.09699234366416931, 0.09383516013622284, -0.16963844001293182, 0.0655815601348877, 0.010390283539891243, -0.01593460887670517, -0.03301285579800606, -0.12383557111024857, -0.034732792526483536, -0.13719014823436737, 0.012526638805866241, -0.07057026773691177, 0.09411977976560593, 0.1157202273607254, -0.10474403202533722, 0.1301887035369873, -0.10342428833246231, -0.14477962255477905, -0.06317394971847534, -0.028270162642002106, -0.02538657747209072, 0.03395703434944153, 0.05331500992178917, 0.03486664593219757, -0.11067578196525574, -0.034955497831106186, 0.040040627121925354, -0.0638045072555542, -0.072133868932724, 0.020377717912197113, -0.05918807163834572, -0.22820182144641876, 0.06672955304384232, 0.12276523560285568, 0.14831620454788208, 0.2796674966812134, -0.03279835730791092, 0.004041357431560755, -0.309474915266037, 0.17454229295253754, 0.05759787559509277, 0.12452816963195801, -0.11516758799552917, 0.19922903180122375, 0.034614019095897675, -0.04531054198741913, 0.15674839913845062, -0.07640037685632706, 0.15484535694122314, -0.08362632989883423, -0.030223548412322998, 0.004525394178926945, 0.052763715386390686, 0.015556727536022663, 0.042062245309352875, -0.019103655591607094, -0.005903128534555435, -0.004692946095019579, 0.006516618654131889, 0.09009778499603271, 0.1063438281416893, 0.06663312762975693, -0.04346001148223877, -0.01411005575209856, 0.06960184127092361, -0.16749224066734314, -0.03586858510971069, 0.120720773935318, -0.04025287553668022, -7.984771660622921e-33, -0.11206232011318207, 0.05631696805357933, 0.040260784327983856, -0.02117341198027134, -0.07740689814090729, -0.038541149348020554, 0.10319791734218597, 0.08754585683345795, -0.01592441275715828, -0.0885889083147049, -0.07181336730718613, 0.08465774357318878, -0.1485542356967926, 0.03286358341574669, -0.014026504941284657, 0.0018335807835683227, 0.0920693501830101, -0.18955311179161072, 0.024779319763183594, -0.05819249898195267, 0.0924454778432846, 0.1837347447872162, -0.0868147686123848, 0.07691264152526855, 0.01174144633114338, 0.05579681694507599, 0.042318195104599, 0.229102224111557, 0.027408936992287636, -0.1700567603111267, 0.029570147395133972, -0.035542771220207214, -0.1582842767238617, 0.09396831691265106, 0.007443246431648731, -0.06489501893520355, -0.04733625054359436, -0.10554711520671844, -0.05252451449632645, -0.07395987212657928, 0.15410873293876648, 0.10640773177146912, -0.009554358199238777, 0.045143626630306244, 0.07894207537174225, 0.018219076097011566, -0.08393938094377518, 0.0013056294992566109, 0.2805604338645935, 0.14571475982666016, 0.02133653312921524, 0.008459772914648056, -0.04700681194663048, 0.1842500865459442, -0.13179758191108704, -0.0026856306940317154, 0.0016452725976705551, 0.08418558537960052, -0.15869751572608948, 0.0779600739479065, 0.040416356176137924, 0.10997772216796875, -0.012378985062241554, 0.06571249663829803, 0.058104462921619415, 0.07071831822395325, -0.03130194544792175, -0.033973969519138336, 0.055180907249450684, 0.01337733119726181, 0.06681913882493973, -0.06269624084234238, 0.07246114313602448, -0.1468593180179596, 0.03650457039475441, 0.3310878872871399, -0.09438299387693405, -0.19228245317935944, -0.08898264169692993, 0.004710682667791843, 0.1334846019744873, 0.05927981436252594, 0.09067240357398987, -0.005558567121624947, -0.09817586839199066, 0.16257484257221222, -0.023581378161907196, -0.016438711434602737, -0.05630943924188614, 0.032255709171295166, -0.041797563433647156, -0.19431303441524506, -0.0770755410194397, -0.017459172755479813, 0.040144771337509155, -9.96422642174366e-08, 0.03702443093061447, -0.06870836019515991, 0.07752130925655365, -0.03754042834043503, 0.12829427421092987, -0.061204925179481506, 0.03157249093055725, -0.07689903676509857, 0.16491267085075378, 0.10394981503486633, 0.0554964542388916, 0.050356559455394745, -0.2094324827194214, 0.05644635856151581, -0.1525478959083557, -0.011249074712395668, -0.11209448426961899, 0.033957451581954956, 0.018936200067400932, -0.14519675076007843, -0.07652552425861359, 0.06345571577548981, 0.058330245316028595, -0.14157219231128693, 0.081584133207798, -0.08479011058807373, -0.1087331473827362, -0.017289573326706886, -0.017244350165128708, 0.0084061399102211, 0.07837161421775818, -0.02526235207915306, 0.07437397539615631, 0.07418301701545715, -0.039233267307281494, -0.09536866843700409, 0.04572663828730583, 0.06250142306089401, 0.036237481981515884, 0.10404825210571289, 0.022581852972507477, -0.0564868189394474, 0.013473739847540855, 0.013195876032114029, -0.029116103425621986, -0.06734161823987961, -0.1515980213880539, 0.012560101225972176, 0.04025064408779144, -0.27426785230636597, 0.16967666149139404, -0.07884390652179718, 0.01851925440132618, 0.065948486328125, 0.052898090332746506, 0.011123121716082096, -0.22349974513053894, -0.0012144800275564194, -0.15254557132720947, 0.0013671829365193844, 0.19345623254776, -0.2888784408569336, 0.01653219573199749, 0.11609828472137451], "changes": {"1wk": 10.638296433266428, "1mo": 50.354605372010354}}, {"text": "Biofrontera Inc. Announces 100 RhodoLED\u00ae XL Machines Now Placed in US Market Biofrontera Inc. Mon, Dec 23, 2024, 5:30 PM 6 min read In This Article: BFRI BFRIW Biofrontera Inc. Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch. The RhodoLED XL is approved by the FDA in combination with Ameluz \u00ae (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp. Biofrontera\u2019s RhodoLED XL and BF-RhodoLED lamps deliver red light energy using long-lasting light-emitting diode (LED) arrays. WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the 100 th commercial RhodoLED \u00ae XL Lamp has now been installed in the US market. The RhodoLED XL was approved by the FDA for use in combination with Ameluz \u00ae in 2022 and was launched in June of this year. Since then, it has seen rapid adoption by offices who had previously used Ameluz and those who are new to the product, with 100 now being installed since launch. The main difference between the company\u2019s existing BF-RhodoLED lamp and the new RhodoLED XL is the number of LED panels which allows a larger surface area to be illuminated during a single PDT treatment with Ameluz \u00ae . \u201cWe are delighted that the RhodoLED XL Lamp has had such an enthusiastic reaction from dermatologists who perform PDT, with more than 10% of offices using Ameluz already installing one\u201d said Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. \u201cIt is remarkable to have placed this many in such a short span of time post launch, and our customers have been very complimentary about the level of service we have delivered both in the lead up to installation, and with the training and support afterwards,\u201d he continued. After a three-month evaluation of the RhodoLED XL, Dr. Aaron Hoover of Front Range Dermatology, Colorado was so impressed with its performance that his practice decided to purchase not one but two units, including the 100 th installed RhodoLED XL lamp. \u201cWe were thoroughly impressed by the lamp\u2019s robust yet elegant design, as well as its exceptional maneuverability and adjustability, which made it ideal for Photodynamic Therapy (PDT) treatments in our offices,\u201d Dr. Hoover explained. \u201cThe larger illumination area has significantly increased our patient throughput while also enhancing the overall quality of care and patient experience.\u201d Dr. Hoover also noted the high level of satisfaction among both staff and patients with the outcomes of using Ameluz PDT in conjunction with the RhodoLED XL. \u201cAdditionally, the Biofrontera team made the purchase and transition to the XL an entirely seamless process for us,\u201d he added. Story Continues \u201cWe were pleased to receive FDA approval for the use of up to 3 tubes of Ameluz \u00ae in one treatment in October of this year\u201d stated Dr Luebbert. \u201cWith this capability and the larger illumination area of the RhodoLED XL our physicians can now treat a larger surface area on the face and scalp at one time which is efficient for the office and convenient for their patients\u201d he concluded. About Actinic Keratosis AK is the most common pre-cancerous skin lesion caused by chronic sun exposure that may, if left untreated, develop into life-threatening skin cancer called squamous cell carcinoma. AKs typically appear on sun-exposed areas such as the face, bald scalp, arms or the back of the hands. In 2020, approximately 58 million people in the US were affected by AK and 13 million AK treatments were performed. 2 1. https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/ 2. https:// www.skincancer.org/skin-cancer-information/actinic-keratosis/ About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz \u00ae with the RhodoLED \u00ae lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter . Forward-Looking Statements Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company\u2019s relationship with its licensors; the ability of the Company\u2019s licensors to fulfill their obligations to the Company in a timely manner; the Company\u2019s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company\u2019s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company\u2019s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz \u00ae in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company\u2019s expectations; the Company\u2019s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), which can be obtained on the SEC\u2019s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management\u2019s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact: Investor Relations Andrew Barwicki 1-516-662-9461 ir@bfri.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-12-23T17:30:00", "sentiment": {"score": 0.4281901093199849, "confidence": 0.4387412667274475, "probabilities": {"positive": 0.4387412667274475, "negative": 0.010551157407462597, "neutral": 0.5507076382637024}}, "embedding": [-0.05380663648247719, -0.07390809804201126, -0.07625712454319, -0.06683976948261261, 0.14799071848392487, -0.06115102022886276, -0.03198505565524101, 0.2962604761123657, -0.01155109703540802, 0.07144616544246674, -0.018070679157972336, 0.06371460855007172, 0.03310363367199898, 0.07800151407718658, -0.03480958193540573, 0.018847111612558365, 0.018489783629775047, -0.130465567111969, -0.04366318881511688, 0.04608546197414398, -0.01623218134045601, -0.10331028699874878, -0.02939963899552822, -0.007479369640350342, -0.0703955590724945, 0.11681534349918365, -0.09899675846099854, -0.07023287564516068, -0.1259153187274933, -0.08330574631690979, 0.15222856402397156, 0.07664111256599426, -0.022190414369106293, -0.10748064517974854, -0.08141259849071503, 0.003769063390791416, -0.1298391968011856, -0.06843648105859756, -0.0828719362616539, 0.0626862645149231, -0.10805514454841614, -0.12325288355350494, -0.09778180718421936, -0.00927966833114624, 0.08689764887094498, -0.08842631429433823, -0.004662357736378908, 0.002194196218624711, 0.009453071281313896, -0.04386860877275467, -0.047097742557525635, -0.12687864899635315, -0.03265482187271118, 0.14193099737167358, 0.0008181175217032433, 0.0702986791729927, -0.16057968139648438, -0.03872142732143402, -0.036775484681129456, 0.0015676869079470634, -0.032281748950481415, -0.09880636632442474, 0.004440033808350563, -0.0279063880443573, 0.023107655346393585, -0.008299470879137516, -0.12863501906394958, -0.20215775072574615, 0.10997001826763153, -0.02773771621286869, -0.03676215559244156, -0.0227215439081192, 0.04641037434339523, 0.05533798784017563, -0.06732769310474396, 0.09406520426273346, 0.19867652654647827, 0.1175120621919632, 0.1305621713399887, -0.0546104721724987, 0.115064337849617, 0.11224982142448425, 0.016748368740081787, 0.0468011200428009, 0.10918358713388443, 0.047269102185964584, -0.016737081110477448, 0.09536182880401611, -0.052713051438331604, 0.021487977355718613, 0.09066885709762573, 0.11197075247764587, -0.06766822189092636, 0.0051528033800423145, -0.09406783431768417, -0.09349555522203445, -0.06871356070041656, 0.04479193314909935, -0.03310757875442505, 0.02739260345697403, -0.008412000723183155, -0.16186010837554932, -0.1592034548521042, -0.03613398224115372, -0.1505933403968811, -0.17442214488983154, -0.0038793887943029404, 0.14738845825195312, 0.018180733546614647, -0.028808478266000748, -0.007683147210627794, 0.03090701252222061, -0.06682617962360382, -0.031129028648138046, -0.168490469455719, 0.1148190051317215, -0.006583015434443951, -0.08374936878681183, 0.13690365850925446, -0.13447026908397675, 0.05576321482658386, 0.01851043477654457, 0.0823044404387474, -0.1775778830051422, 0.04936988279223442, -0.08379283547401428, -0.03542976826429367, 1.6209943670932508e-32, 0.028430521488189697, 0.1204950138926506, -0.10302906483411789, 0.0037057576701045036, -0.1233404278755188, 0.15014687180519104, -0.03385930508375168, 0.04937467724084854, 0.014551082625985146, -0.16576308012008667, 0.01293310709297657, 0.16858914494514465, -2.6783905923366547e-05, 0.09416153281927109, -0.036300964653491974, -0.1543506383895874, 0.04488121718168259, 0.07500020414590836, -0.10885300487279892, -0.040718819946050644, 0.026832185685634613, 0.08192332088947296, -0.04584266245365143, 0.11341261863708496, -0.02562674880027771, 0.08537362515926361, -0.10183554142713547, 0.00442919647321105, -0.05436108261346817, 0.0870538279414177, -0.027736395597457886, 0.042885053902864456, 0.02593940496444702, 0.011204637587070465, -0.1641804575920105, -0.02846001461148262, -0.07104627043008804, -0.2329556792974472, -0.03007158264517784, -0.06270673871040344, -0.035115797072649, 0.26846805214881897, 0.003318341448903084, 0.020076600834727287, 0.1361556053161621, 0.11773839592933655, -0.15758474171161652, 0.11950420588254929, 0.03513457253575325, 0.03964141011238098, -0.08941742777824402, 0.0604003444314003, 0.07461877167224884, -0.010373873636126518, -0.019608402624726295, 0.05885278433561325, -0.16418172419071198, -0.033365748822689056, 0.1578161120414734, 0.10993701964616776, 0.032797958701848984, 0.132663756608963, -0.0770355761051178, 0.05801590532064438, -0.08185574412345886, 0.03122600167989731, 0.13489319384098053, 0.11383532732725143, -0.15066710114479065, 0.03757669776678085, 0.02691982313990593, 0.00797349028289318, 0.12575975060462952, -0.007309766486287117, 0.10347466170787811, -0.06220271438360214, 0.10086634755134583, 0.20196938514709473, -0.06680460274219513, -0.09788038581609726, -0.07912158221006393, 0.14325186610221863, -0.004802261013537645, -0.029180973768234253, 0.04788225144147873, 0.06127411872148514, 0.024148568511009216, 0.07311619818210602, -0.2312743067741394, -0.030429692938923836, 0.17431217432022095, -0.12167154252529144, -0.021090209484100342, 0.08741508424282074, -0.12164338678121567, -1.431279129762134e-32, 0.03479024022817612, -0.023070521652698517, -0.10491500049829483, -0.03640345484018326, 0.13824579119682312, 0.06948049366474152, 0.1732022613286972, -0.015315130352973938, 0.04248092323541641, -0.1250550001859665, 0.10009313374757767, 0.04376880079507828, -0.11346618831157684, 0.03567450866103172, 0.020526878535747528, -0.05004803463816643, -0.07197322696447372, -0.11021862924098969, -0.12337852269411087, 0.009836321696639061, 0.022322675213217735, 0.17388445138931274, -0.058327533304691315, -0.015452377498149872, -0.0828227549791336, 0.04030732065439224, 0.05572161078453064, 0.06722519546747208, -0.02798168919980526, -0.06534749269485474, -0.1111287921667099, 0.02374243177473545, -0.24156294763088226, 0.05659535527229309, 0.007322518154978752, 0.07208192348480225, 0.013698681257665157, -0.08113128691911697, -0.10278808325529099, -0.004577689804136753, 0.1359986960887909, -0.011750632897019386, -0.08485038578510284, 0.017814191058278084, -0.06495698541402817, -0.020482748746871948, -0.1554660201072693, -0.10695843398571014, 0.1074831560254097, 0.023510819301009178, -0.10342305898666382, -0.0035226792097091675, -0.03600116819143295, 0.07014339417219162, -0.11252574622631073, -0.06253919005393982, 0.04144066199660301, 0.096651092171669, -0.13565286993980408, 0.11220157146453857, 0.11556009948253632, -0.010444825515151024, 0.08577826619148254, 0.0242500901222229, 0.07725174725055695, 0.10023968666791916, 0.104122593998909, 0.04048411548137665, 0.06186026707291603, -0.013791544362902641, 0.07920211553573608, -0.009328699670732021, -0.019611550495028496, -0.018834661692380905, -0.02273400127887726, -0.020336749032139778, -0.0037808362394571304, -0.15330907702445984, -0.18967591226100922, -0.015659678727388382, -0.0545036643743515, -0.04635336250066757, 0.06883751600980759, 0.044199831783771515, 0.12790432572364807, -0.010384559631347656, 0.004006326664239168, -0.08712734282016754, -0.1385280340909958, 0.057950712740421295, -0.008091007359325886, 0.0072584981098771095, -0.06326951086521149, 0.1484876573085785, 0.16494393348693848, -1.0095381242081203e-07, 0.036691512912511826, -0.011933909729123116, 0.06061085686087608, -0.04218922555446625, 0.11617471277713776, -0.0478515625, 0.026465345174074173, 0.04798368364572525, -0.04330924153327942, 0.07764148712158203, 0.024608157575130463, 0.11510951071977615, -0.00209232815541327, 0.012970667332410812, 0.006158875767141581, 0.08235526084899902, -0.07298870384693146, -0.02310793101787567, -0.0613543838262558, -0.06670036166906357, -0.17164720594882965, -0.02880551666021347, 0.05890599638223648, -0.0773090049624443, 0.050086610019207, 0.06764563173055649, 0.07002238184213638, 0.041364334523677826, -0.003537113545462489, -0.014041727408766747, 0.07270091772079468, 0.009662633761763573, 0.16154351830482483, 0.035747237503528595, -0.034840185195207596, -0.10819198191165924, -0.024859899654984474, 0.1143949031829834, -0.003976127132773399, 0.058637429028749466, -0.0708618313074112, -0.07393775135278702, -0.0011781200300902128, 0.07224719226360321, 0.051784105598926544, -0.09336791932582855, -0.11917643249034882, 0.007887081243097782, 0.0014270818792283535, -0.013655087910592556, -0.012184622697532177, -0.04841603338718414, -0.01887546479701996, -0.05443047732114792, -0.06642507016658783, -0.06092994660139084, -0.022135818377137184, -0.006317934952676296, 0.06979192048311234, 0.027616530656814575, 0.14658203721046448, -0.12119888514280319, 0.16644850373268127, 0.11725324392318726], "changes": {"1wk": 9.900992553078233, "1mo": 0.9900980750178164}}, {"text": "Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ... GuruFocus News Fri, Nov 15, 2024, 10:12 AM 3 min read In This Article: BFRIW Release Date: November 14, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Biofrontera Inc ( NASDAQ:BFRI ) reported a significant increase in the total number of Ameluz tubes ordered, alongside a reduction in costs. The company improved its FDA label, allowing the use of up to three tubes of Ameluz per treatment, enhancing flexibility for healthcare providers. Outstanding clinical results were achieved for a new indication, with a high degree of statistical significance in the superficial BCC phase three study. The launch of the RDO LED XL lamp has been successful, with 105 new lamps installed in the first three quarters of 2024. Biofrontera Inc ( NASDAQ:BFRI ) has taken control over clinical trials, leading to a reduced transfer price for Ameluz, which is expected to improve profitability. Negative Points Revenues in the third quarter were impacted by delayed shipments due to Hurricane Milton, affecting growth figures. The net loss for the third quarter of 2024 was $5.7 million, although this was an improvement from the previous year. Adjusted EBITDA for the third quarter was negative $4.6 million, reflecting higher general and administrative costs. Legal expenses increased by $0.8 million due to complaints filed by Doa Pharmaceuticals, impacting financial performance. The company is still not cash flow break-even and anticipates reaching this milestone towards the end of 2025 or early 2026. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with BFRI. Q : When will the cost of revenue start to reflect the new 25% rate rather than the older 50% rate? A : Fred Leffler, CFO: We expect to see that impact in the fourth quarter as we needed to go through our older inventory first. Q : Do you still expect to be cash flow break-even by the end of next year and to grow revenue by 20% over 2023? A : Fred Leffler, CFO: We expect revenue growth similar to prior years, in the mid to high 10s, and anticipate reaching cash flow break-even towards the end of 2025 or early 2026. Q : With the shipments delayed to October, did you apply the October 1 price hike or maintain the older price? A : Fred Leffler, CFO: We grandfathered in the older price as all orders were placed in Q3, despite the shipping delays caused by weather. Q : Can you provide the enrollment numbers for the Acne and peripheral AK trials? A : Herman, CEO: Enrollment for the peripheral AK trial is 130 of 165 patients, and for the Acne study, it is 106 of 126. Q : How do you see the fourth quarter developing in terms of revenue after the price increase? A : Fred Leffler, CFO: We expect growth in line with prior years, with a strong Q4 anticipated. The price increase was 5%, similar to last year, and Q4 is typically our strongest quarter. Story Continues Q : Has there been any customer response to the new three tubes approval? A : Herman, CEO: We have not seen a response yet as we wanted to ensure reimbursement processes were in place before promoting the new labeling. We expect to see uptake starting in December. For the complete transcript of the earnings call, please refer to the full earnings call transcript . This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-15T10:12:56", "sentiment": {"score": 0.7928809300065041, "confidence": 0.8787343502044678, "probabilities": {"positive": 0.8787343502044678, "negative": 0.08585342019796371, "neutral": 0.03541224077343941}}, "embedding": [-0.06701379269361496, -0.09259544312953949, -0.06914567202329636, -0.08874689042568207, 0.06453756242990494, -0.02005317620933056, -0.12312810868024826, 0.24091364443302155, 0.16596464812755585, 0.12349963933229446, -0.061341673135757446, 0.05678316205739975, -0.0005565726314671338, -0.00685476278886199, -0.05912904068827629, -0.02063722163438797, 0.0030187657102942467, -0.10186053067445755, -0.05682384967803955, 0.07350153475999832, 0.01875072717666626, -0.02023710310459137, -0.033610641956329346, 0.06211308017373085, 0.017963722348213196, 0.010430718772113323, -0.09606236964464188, -0.02820505201816559, -0.089798703789711, -0.060864757746458054, 0.08588800579309464, 0.16896432638168335, 0.08679869771003723, -0.07844746112823486, -0.03106299415230751, -0.0046134269796311855, -0.013957755640149117, -0.046335041522979736, -0.06394129991531372, 0.022137999534606934, -0.02035459689795971, -0.12092980742454529, -0.1405077576637268, -0.01566294953227043, 0.11434055864810944, -0.1243266686797142, -0.003316681832075119, 0.023374304175376892, 0.11200156062841415, 0.0030086233746260405, -0.15687109529972076, -0.14468419551849365, -0.03597700968384743, 0.09398716688156128, -0.049081698060035706, 0.03872155025601387, 0.001723984256386757, -0.1400856077671051, 0.015571888536214828, 0.09055468440055847, -0.0798766240477562, -0.04272054135799408, 0.07645102590322495, 0.04669550061225891, 0.24078667163848877, 0.09492148458957672, -0.12583178281784058, -0.0916287899017334, -0.0370270200073719, 0.0036681145429611206, -0.0031367018818855286, -0.1360713541507721, -0.00643669068813324, -0.0568479560315609, -0.07248613238334656, 0.22308692336082458, 0.15693967044353485, 0.1965465098619461, 0.09986613690853119, -0.1184564009308815, 0.06976741552352905, -0.0017842298839241266, 0.017693504691123962, -0.06278866529464722, -0.06535559892654419, 0.04561930522322655, 0.09493009746074677, 0.015876978635787964, 0.020985601469874382, 0.06771139800548553, 0.10353948175907135, -0.041839297860860825, 0.0028535937890410423, 0.006378098390996456, 0.0002226550132036209, -0.04230131581425667, -0.09330902993679047, -0.11154426634311676, 0.055312469601631165, -6.458302959799767e-05, 0.09223644435405731, -0.002317371778190136, -0.08645018935203552, -0.048112452030181885, -0.14893248677253723, -0.07196696102619171, 0.08022284507751465, 0.0456034392118454, 0.0026869582943618298, 0.017275044694542885, -0.09298212081193924, 0.08511966466903687, -0.04906059801578522, -0.10564947128295898, -0.11316254734992981, 0.17427298426628113, -0.043595828115940094, -0.002862259978428483, 0.16425183415412903, -0.06809640675783157, 0.06352219730615616, 0.049915168434381485, -0.016119584441184998, -0.09015482664108276, -0.0034607183188199997, -0.004276745021343231, -0.1446205973625183, 1.283271607492543e-32, 2.347724512219429e-05, 0.019984852522611618, 0.0017435962799936533, -0.07417148351669312, -0.0867789164185524, 0.10242164134979248, 0.006436128634959459, -0.056252166628837585, -0.003940600901842117, -0.0764666497707367, -0.1268492043018341, 0.10673654824495316, -0.06827390938997269, -0.06571152806282043, 8.516747038811445e-05, -0.2070561796426773, -0.04446621239185333, 0.031188996508717537, -0.05463016778230667, -0.02984706312417984, 0.035273779183626175, -0.09981590509414673, -0.053826309740543365, -0.04611293599009514, 0.10248643159866333, 0.06864321231842041, -0.1313857138156891, 0.06459996104240417, -0.11091624200344086, 0.06426279246807098, -0.04708867147564888, 0.02910616807639599, -0.0038094427436590195, -0.036237623542547226, -0.1108192652463913, -0.10995042324066162, -0.09525872766971588, -0.11928711831569672, 0.0037700317334383726, 0.0504017099738121, -0.10982552170753479, 0.18397337198257446, -0.03994438797235489, -0.06429578363895416, 0.06361205875873566, -0.01566733978688717, 0.0033933687955141068, -0.02305256575345993, 0.04227648675441742, -0.011283831670880318, -0.08394026756286621, 0.007454805076122284, -0.02898094803094864, -0.09042541682720184, 0.023079797625541687, -0.02262192592024803, -0.06316470354795456, -0.12282230705022812, 0.08150152117013931, 0.13026756048202515, 0.05607234686613083, 0.1473504602909088, -0.1280631273984909, -0.013403273187577724, -0.20932984352111816, 0.1365629881620407, 0.12246948480606079, 0.13103964924812317, -0.047151271253824234, 0.0698016956448555, -0.005198134575039148, 0.025406036525964737, 0.11515261232852936, 0.020742716267704964, 0.0882415920495987, -0.08422951400279999, 8.474016794934869e-05, 0.10328678786754608, 0.01120314933359623, -0.038604654371738434, 0.0067085158079862595, -0.017958421260118484, 0.04070685803890228, 0.03859245032072067, 0.07188884913921356, 0.11133255064487457, 0.1156557947397232, 0.012017901986837387, -0.19229018688201904, -0.03897954523563385, 0.09818263351917267, -0.06278274208307266, 0.019263600930571556, 0.2629406154155731, -0.04408751800656319, -1.1413539541125773e-32, -0.023993633687496185, 0.06649073958396912, -0.01008029468357563, -0.0998317152261734, -0.019271880388259888, 0.058013275265693665, 0.18701010942459106, -0.014138857834041119, 0.04081197828054428, -0.07255145162343979, -0.013040597550570965, 0.10035986453294754, -0.03492221608757973, -0.047670554369688034, -0.04612527787685394, -0.06843118369579315, 0.026063039898872375, -0.17547115683555603, -0.09169922769069672, -0.02703823149204254, 0.12364086508750916, 0.1806747317314148, -0.11510992050170898, -0.02722015231847763, -0.0712490975856781, 0.08943700790405273, 0.0499248169362545, 0.11204947531223297, -0.016839725896716118, -0.07922454178333282, -0.08792907744646072, 0.00300617516040802, -0.21199697256088257, 0.0873442217707634, 0.04410190507769585, -0.081394262611866, 0.04251210391521454, -0.11450041830539703, -0.030019128695130348, -0.10202472656965256, 0.1139931008219719, 0.12292837351560593, -0.07836559414863586, -0.001597866415977478, 0.019107751548290253, -0.017902560532093048, -0.023371068760752678, -0.05695832520723343, 0.24760501086711884, 0.07298371940851212, -0.05669634789228439, -0.023026537150144577, 0.013077656738460064, 0.15165668725967407, -0.10903515666723251, -0.017106521874666214, 0.11609196662902832, 0.00888556893914938, -0.12302878499031067, 0.04898571968078613, 0.059748969972133636, 0.09747383743524551, 0.06818488240242004, -0.05428318306803703, 0.16765666007995605, 0.09792342782020569, 0.11284103244543076, -0.06233673170208931, 0.12463323026895523, -0.010546630248427391, 0.053687434643507004, -0.04712492600083351, -0.06774534285068512, -0.08266428112983704, 0.04254746437072754, 0.18447135388851166, -0.06246339529752731, -0.15825265645980835, -0.10749509930610657, -0.01782870851457119, -0.00853858795017004, 0.007539459504187107, 0.059629395604133606, 0.07521624863147736, -0.0019905976951122284, 0.03259408473968506, 0.04798628389835358, -0.09838522970676422, -0.03788934648036957, 0.07070355117321014, -0.11608205735683441, -0.029852300882339478, -0.06835488975048065, 0.12258018553256989, 0.07048274576663971, -9.984669446794214e-08, -0.017569387331604958, 0.026376785710453987, 0.015821540728211403, -0.002603802364319563, 0.15338395535945892, -0.14014573395252228, -0.04244112968444824, -0.007084607146680355, 0.0756857842206955, 0.14894430339336395, 0.04012120142579079, 0.13136452436447144, -0.0776243805885315, -0.004230703227221966, -0.04404821991920471, 0.0796482190489769, -0.1059534102678299, 0.010730567388236523, 0.011559009552001953, -0.08780823647975922, -0.10091555118560791, 0.01822672411799431, 0.020376216620206833, -0.05214395374059677, 0.07775229215621948, -0.12161567807197571, 0.011026958003640175, 0.1658850908279419, 0.016736498102545738, 0.03227321431040764, -0.003016651840880513, -0.02143794856965542, 0.10317248106002808, -0.0003123665228486061, -0.053895656019449234, -0.07687751203775406, -0.05464157462120056, 0.10655903816223145, 0.05050177127122879, 0.14775165915489197, 0.05499795451760292, -0.009009881876409054, 0.0749252587556839, 0.015318550169467926, 0.006519520655274391, -0.048707038164138794, -0.20236727595329285, 0.006132571958005428, -0.006115018390119076, -0.1566450595855713, 0.16149117052555084, -0.06745344400405884, 0.029019981622695923, 0.03794534131884575, 0.030654646456241608, -0.05458623915910721, -0.07890824973583221, 0.04669930040836334, -0.026499764993786812, 0.018301265314221382, 0.11944882571697235, -0.22892796993255615, 0.0896807461977005, 0.051754873245954514], "changes": {"1wk": 3.4059911760767427, "1mo": 44.414155794030066}}, {"text": "PREMIUM Biofrontera Shares Jump After Closing Private Placement of $4.2 Million Convertible Note MT Newswires Fri, Nov 22, 2024, 10:22 PM Biofrontera Shares Jump After Closing Private Placement of $4.2 Million Convertible Note PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-22T22:22:21", "sentiment": {"score": 0.05049646832048893, "confidence": 0.06518132984638214, "probabilities": {"positive": 0.06518132984638214, "negative": 0.014684861525893211, "neutral": 0.9201338291168213}}, "embedding": [0.043009690940380096, -0.15655945241451263, -0.046078506857156754, 0.04885287582874298, 0.12715497612953186, -0.00088851572945714, -0.20046228170394897, 0.12078884989023209, 0.13408802449703217, 0.09378793835639954, 0.16161252558231354, 0.245479017496109, -0.09645690768957138, 0.02711530774831772, 0.10392236709594727, -0.008129865862429142, 0.0553370863199234, -0.2573973834514618, -0.037695907056331635, 0.136626198887825, -0.18369925022125244, -0.11788586527109146, -0.006590717937797308, 0.036794062703847885, 0.11648381501436234, 0.14273352921009064, -0.1487143635749817, -0.07125880569219589, -0.0034581429790705442, -0.04195476695895195, 0.03378312662243843, -0.0023610673379153013, 0.08665669709444046, -0.05542841926217079, 0.10693655908107758, -0.09076740592718124, -0.09474867582321167, 0.010147018358111382, 0.01754785142838955, -0.08478513360023499, 0.11590395122766495, -0.10031066834926605, -0.1858837753534317, -0.024411791935563087, 0.005307952873408794, 0.00704910745844245, 0.07414476573467255, 0.09721372276544571, 0.17668548226356506, 0.014070200733840466, -0.042535096406936646, -0.1165524274110794, -0.06954310834407806, -0.033758874982595444, -0.07585294544696808, 0.0916934683918953, -0.01625429466366768, -0.19930587708950043, -0.04647384211421013, 0.014424472115933895, 0.10110986977815628, -0.08509039878845215, -0.054985981434583664, -0.06887836009263992, 0.010116849094629288, 0.03927673399448395, 0.08025789260864258, 0.12576523423194885, 0.06785675138235092, -0.08647844940423965, 0.0991789847612381, 0.10471346229314804, 0.03826956823468208, -0.053391002118587494, 0.0318746343255043, 0.2470230907201767, 0.2128617912530899, 0.006958940532058477, 0.0575072206556797, -0.16108235716819763, 0.04141426086425781, -0.1692322939634323, -0.03700399026274681, -0.04997488111257553, 0.03587794676423073, 0.013272020034492016, 0.07772798836231232, -0.039909448474645615, -0.0886894017457962, -0.045805443078279495, 0.06735078245401382, -0.04675845056772232, 0.06879061460494995, 0.05626162886619568, -0.27441635727882385, -0.053212519735097885, -0.26817312836647034, -0.09539447724819183, 0.006589029915630817, 0.0008221417665481567, 0.09703338891267776, 0.05852501839399338, 0.06941459327936172, 0.06459447741508484, -0.03564736992120743, -0.049288149923086166, -0.006458389572799206, 0.13936595618724823, 0.06313098222017288, 0.09738347679376602, -0.016632722690701485, 0.16090236604213715, 0.006933186668902636, -0.06577832996845245, -0.20870262384414673, 0.2376740425825119, -0.14385490119457245, -0.048952363431453705, 0.24604102969169617, -0.09433924406766891, 0.08027563989162445, 0.16159188747406006, 0.03056117333471775, -0.06867286562919617, -0.07413526624441147, -0.03705552592873573, -0.13760536909103394, 1.609803366999835e-32, -0.05107223987579346, -0.011493902653455734, 0.003949514124542475, -0.08077601343393326, -0.05337974429130554, -0.08288243412971497, 0.01966455765068531, -0.10195673257112503, -0.0075654941610991955, -0.053568240255117416, -0.0745861604809761, 0.10377798229455948, -0.0008381091174669564, 0.03246642276644707, -0.12330297380685806, -0.24086534976959229, 0.020869707688689232, 0.034801043570041656, 0.11651299148797989, 0.0012045158073306084, 0.06963332742452621, 0.01243398804217577, -0.05206777900457382, 0.05761530250310898, -0.019377142190933228, 0.10881958156824112, 0.01704392023384571, -0.04275597631931305, 0.09642206877470016, 0.13732796907424927, -0.1388033926486969, -0.004524859134107828, 0.03415375202894211, -0.06139750778675079, 0.11981842666864395, 0.08044647425413132, 0.020257718861103058, -0.164824977517128, 0.12783415615558624, -0.05195222422480583, -0.009852618910372257, -0.013340188190340996, -0.060721125453710556, 0.02249019593000412, -0.0974951758980751, -0.032900042831897736, -0.06650256365537643, 0.04305601492524147, 0.20426492393016815, 0.06130203604698181, -0.19299505650997162, -0.019704444333910942, -0.1750899702310562, 0.055779386311769485, -0.2051299810409546, -0.05949105694890022, -0.06694227457046509, -0.26164016127586365, 0.03373868390917778, -0.0696026086807251, 0.11144499480724335, 0.16858947277069092, 0.021050911396741867, 0.0053957081399858, -0.2721032500267029, 0.13102932274341583, -0.0274541974067688, -0.029469091445207596, -0.20087701082229614, 0.14522628486156464, 0.08729090541601181, -0.04095869138836861, 0.15791364014148712, -0.09704892337322235, 0.020000195130705833, -0.09885122627019882, -0.045821767300367355, 0.07083087414503098, 0.2504436671733856, 0.05246236175298691, 0.1803913563489914, -0.019226346164941788, 0.0828915610909462, 0.07006897032260895, -0.0008927829330787063, 0.14819790422916412, 0.03359587490558624, -0.0952475368976593, -0.12374448776245117, 0.05153077095746994, -0.05254684016108513, -0.06856042146682739, -0.023866524919867516, 0.1268913596868515, -0.050708189606666565, -1.8200769719692766e-32, -0.1535722315311432, 0.02696787752211094, 0.026042480021715164, -0.09704563021659851, -0.1306406855583191, 0.03353618085384369, -0.0015626077074557543, 0.27999937534332275, -0.04351584613323212, 0.2013474404811859, -0.040377289056777954, 0.2151091992855072, 0.04232680797576904, -0.019398750737309456, -0.032920610159635544, -0.01195105817168951, 0.08652332425117493, -0.12697288393974304, 0.078162781894207, -0.0038147778250277042, -0.06628017127513885, 0.10549332946538925, 0.03423096239566803, 0.24371454119682312, 0.18827097117900848, -0.05211208388209343, 0.0012176029849797487, 0.16418348252773285, 0.14212843775749207, -0.17766523361206055, -0.07804324477910995, -0.06680110096931458, -0.20337846875190735, 0.06608320027589798, -0.008893580175936222, -0.028848202899098396, 0.04887716472148895, -0.008044751361012459, -0.09192397445440292, -0.024713030084967613, 0.10962607711553574, 0.006756917107850313, 0.0015102634206414223, 0.09055085480213165, 0.1361115425825119, 0.06312885880470276, -0.1803090125322342, -0.05868484824895859, 0.12691716849803925, 0.09856955707073212, -0.025140933692455292, 0.018261274322867393, 0.178879052400589, 0.06001308560371399, -0.19224324822425842, 0.025238247588276863, 0.16811451315879822, 0.1478685736656189, -0.048501309007406235, -0.06166583672165871, 0.15747341513633728, 0.06686380505561829, -0.1735500544309616, -0.14137573540210724, -0.003086377866566181, -0.0495094433426857, 0.07612474262714386, -0.046480774879455566, -0.11994073539972305, 0.049938641488552094, -0.017454663291573524, -0.06843999773263931, 0.004887522663921118, -0.27600929141044617, 0.01951928250491619, 0.2606300711631775, -0.10537727177143097, -0.1151152104139328, -0.023417482152581215, -0.000246835348661989, -0.006018715910613537, -0.04172483831644058, 0.15295825898647308, -0.0865231528878212, 0.032433394342660904, -0.01946772076189518, 0.05551828816533089, -0.02573578432202339, -0.22829410433769226, 0.059905167669057846, -0.1564697027206421, -0.14768099784851074, 0.01645720563828945, 0.027690716087818146, -0.052099138498306274, -1.004549332606075e-07, 0.07024458795785904, 0.06132785975933075, 0.10595996677875519, -0.06437624245882034, 0.09931991249322891, -0.15939494967460632, -0.014441163279116154, 0.037859052419662476, 0.14023326337337494, 0.1764223873615265, -0.07661239057779312, -0.026814352720975876, -0.13972660899162292, -0.0545559823513031, -0.2411036342382431, 0.024884715676307678, -0.1624748259782791, -0.03055422566831112, 0.018152808770537376, -0.20625630021095276, 0.011103939265012741, 0.07522595673799515, 0.1210431307554245, -0.10019629448652267, 0.056060791015625, 0.015947479754686356, 0.0407169908285141, -0.047262921929359436, 0.014135152101516724, -0.029697787016630173, -0.03523728996515274, 0.009143848903477192, -0.0010113073512911797, 0.052332181483507156, -0.0947737917304039, 0.03147183358669281, 0.05350908264517784, 0.10069142282009125, -0.04436281695961952, 0.10216109454631805, 0.0340934619307518, -0.11992403864860535, -0.04747442156076431, 0.0962100401520729, 0.05641414225101471, -0.014171158894896507, -0.20834754407405853, -0.04852788522839546, 0.09997046738862991, -0.13559597730636597, 0.09918222576379776, -0.15124282240867615, -0.1002768874168396, -0.003782739629969001, -0.04984019324183464, -0.034452032297849655, -0.14563646912574768, 0.022952251136302948, -0.07663128525018692, 0.03416268527507782, 0.14717194437980652, -0.283543199300766, -0.197268545627594, 0.17629875242710114], "changes": {"1wk": 3.448272554637248, "1mo": 12.528731836512272}}, {"text": "Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note Biofrontera Inc. Fri, Nov 22, 2024, 5:10 PM 4 min read In This Article: BFRI BFRIW Biofrontera Inc. WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the \u201cNote\u201d) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company\u2019s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder\u2019s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes. The proceeds from this financing will primarily support Biofrontera\u2019s general operations and strategic investments, including the Company\u2019s commercial and clinical development initiatives aimed at driving continued sustainable growth. \u201cWith our revenues on a steady upward trajectory, the proceeds from this convertible note provide a solid foundation to meet our financial objectives for 2025 and beyond,\u201d said Prof. Hermann Luebbert, CEO of Biofrontera. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz \u00ae with the RhodoLED \u00ae lamp series for PDT of Actinic Keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers 1 . The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X . 1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/ Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a \u201csafe harbor\u201d for forward-looking statements. Certain statements in this press release constitute \u201cforward-looking statements\u201d. Such statements include estimates of our expenses, future revenue, capital requirements, our need for additional financing, statements regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing licensed products to market, the timeline for regulatory review and approval of our licensed products, and other statements that are not historical facts. The words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d, \u201ctarget\u201d, \u201cgoal\u201d, \u201cassume\u201d, \u201cwould\u201d, \u201ccould\u201d or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should read this press release with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. Factors that may cause such differences include, but are not limited to, those identified in Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our other filings with the SEC. We urge investors and security holders to read those documents free of charge at the SEC\u2019s web site at www.sec.gov . We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. Story Continues Contacts Investor Relations Andrew Barwicki 1-516-662-9461 ir@bfri.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-22T17:10:00", "sentiment": {"score": 0.08563108928501606, "confidence": 0.09558461606502533, "probabilities": {"positive": 0.09558461606502533, "negative": 0.00995352678000927, "neutral": 0.8944618701934814}}, "embedding": [-0.08178718388080597, -0.052841633558273315, -0.10588245093822479, -0.16100364923477173, -0.05770263820886612, -0.006697365082800388, -0.057279910892248154, 0.20971305668354034, 0.1515411138534546, 0.07678452879190445, 0.04947401210665703, 0.04341188818216324, -0.0164119154214859, 0.06636010110378265, -0.010848550125956535, -0.043963320553302765, -0.05828600749373436, -0.034277092665433884, -0.08091704547405243, 0.16936852037906647, -0.08412832021713257, -0.00306718610227108, 0.00419057160615921, 0.03195104002952576, 0.03367035835981369, 0.01826324686408043, -0.07333189249038696, -0.042127374559640884, -0.06796285510063171, -0.03629360720515251, 0.11677805334329605, 0.09302821010351181, 0.10172511637210846, -0.05868971720337868, 0.004130243323743343, 0.038360435515642166, -0.16363325715065002, 0.01436343789100647, -0.02417350560426712, 0.016840845346450806, -0.018492814153432846, -0.01168660819530487, -0.08116067945957184, -0.03573160246014595, -0.016462232917547226, -0.08067313581705093, -0.05257800221443176, 0.059468112885951996, 0.0533057264983654, 0.042694028466939926, -0.1408894807100296, -0.09571847319602966, -0.1040235310792923, 0.13647767901420593, -0.05997448414564133, 0.026172662153840065, -0.025811564177274704, -0.0347285196185112, -0.013570547103881836, 0.015559080988168716, 0.030178070068359375, -0.012856214307248592, 0.01393098384141922, -0.044506464153528214, 0.1692538857460022, -0.03515898808836937, 0.0429081991314888, 0.007892715744674206, -0.0460202693939209, 0.017635947093367577, 0.06989990174770355, -0.06883642077445984, -0.06855694949626923, 0.06328360736370087, -0.16060307621955872, 0.1673492193222046, 0.05455814301967621, 0.14249944686889648, 0.09574799239635468, -0.17877604067325592, 0.04459338262677193, 0.08941933512687683, 0.013400902971625328, -0.0925106629729271, -0.01269181352108717, -0.041092321276664734, 0.01739596389234066, 0.07193215191364288, 0.07512782514095306, 0.05814135819673538, 0.02219618856906891, -0.03606777265667915, 0.05626561492681503, -0.07677073776721954, -0.07850759476423264, -0.04485776275396347, -0.11570024490356445, -0.05187089741230011, 0.001303344964981079, -0.0060693491250276566, 0.05827922374010086, -0.026488017290830612, -0.07548460364341736, -0.005412548780441284, -0.07006515562534332, -0.049233995378017426, 0.03139939159154892, 0.009480500593781471, 0.04836694523692131, 0.022825606167316437, -0.1152573898434639, 0.16355499625205994, -0.015437345951795578, -0.05250256508588791, -0.13622838258743286, 0.08132487535476685, -0.08992618322372437, -0.0553869791328907, 0.2368079572916031, -0.13001307845115662, 0.061018288135528564, 0.03336367756128311, 0.015224776230752468, -0.1031583771109581, -0.045248813927173615, -0.12060988694429398, -0.1408364474773407, 7.71284602181514e-33, -0.0019336396362632513, 0.01915312185883522, 0.009562015533447266, 0.014325632713735104, -0.06400211155414581, -0.027364006265997887, -0.04124223440885544, -0.04417816922068596, -0.1285886913537979, -0.061092302203178406, -0.045540183782577515, 0.05645552650094032, 0.019572405144572258, 0.06577916443347931, -0.030862649902701378, -0.06985947489738464, 0.0018144971691071987, 0.016916325315833092, 0.11885271966457367, -0.023835601285099983, 0.051282476633787155, 0.10966193675994873, -0.024534691125154495, 0.09677930176258087, -0.02653110772371292, -0.0530233196914196, -0.12172701209783554, -0.02160324528813362, -0.012048945762217045, 0.04647788405418396, -0.010372912511229515, 0.0004131714813411236, -0.008016273379325867, -0.08732815086841583, 0.025593630969524384, -0.0298529714345932, -0.06531417369842529, -0.14486509561538696, 0.07771474868059158, 0.06222895532846451, -0.006083822809159756, 0.04013470560312271, -0.019141217693686485, -0.04326120764017105, 0.018792269751429558, 0.07192245125770569, -0.07210042327642441, 0.122564896941185, 0.05065208673477173, 0.10982287675142288, -0.11182398349046707, -0.07102763652801514, -0.04058348014950752, -0.00389007106423378, -0.1325242668390274, -0.028615759685635567, -0.12103903293609619, -0.13104447722434998, 0.015599623322486877, 0.06020651012659073, -0.032880932092666626, 0.12505459785461426, -0.06957994401454926, 0.07236519455909729, -0.21391497552394867, 0.08009274303913116, 0.021118901669979095, -0.04462512582540512, 0.004297660663723946, 0.004543591756373644, -0.028960833325982094, 0.0023375856690108776, 0.14136557281017303, 0.007771032862365246, 0.09811784327030182, -0.133784219622612, 0.12025000900030136, 0.11890149861574173, 0.023972095921635628, 0.009212999604642391, -0.06217105686664581, 0.10470952093601227, 0.00992506742477417, 0.040753450244665146, -0.003785167820751667, 0.06712845712900162, 0.022601403295993805, -0.037915848195552826, -0.17079663276672363, 0.011468327604234219, 0.03366902098059654, -0.15399904549121857, -0.007119657471776009, 0.17370595037937164, -0.012600638903677464, -9.413977365286999e-33, -0.04651697352528572, -0.051007505506277084, -0.024043232202529907, -0.10710299015045166, -0.017082367092370987, 0.1131708100438118, 0.07631049305200577, -0.02116473764181137, -0.061083558946847916, -0.02225809171795845, -0.06204015389084816, 0.07270874828100204, 0.02920304238796234, -0.06940492242574692, -0.09056531637907028, -0.048599228262901306, -0.010450334288179874, -0.024699382483959198, -0.042752705514431, 0.0266644936054945, 0.013172454200685024, 0.11874474585056305, 0.019733387976884842, 0.13967418670654297, 0.08610499650239944, 0.08150048553943634, -0.06731193512678146, 0.10661184042692184, 0.07352223992347717, -0.08671921491622925, -0.06679622828960419, -0.022919856011867523, -0.2859914302825928, 0.022211657837033272, -0.03227478265762329, -0.10895361006259918, 0.05542799085378647, -0.07895414531230927, -0.05139108747243881, 0.03676249831914902, 0.09610138088464737, 0.06999687850475311, -0.002288450486958027, 0.08822507411241531, 0.03442362695932388, -0.080906942486763, -0.03868316859006882, -0.10917118191719055, 0.08699292689561844, 0.07754239439964294, 0.015721037983894348, 0.03470577672123909, 0.17851796746253967, 0.10462284088134766, -0.07642033696174622, 0.013401901349425316, 0.1900578737258911, 0.032582011073827744, -0.07616492360830307, 0.032208867371082306, 0.1681566834449768, 0.0687042698264122, 0.013465477153658867, 0.014611378312110901, 0.05918720364570618, -0.004870050121098757, -0.046009667217731476, 0.018254416063427925, -0.04065193980932236, 0.03834603354334831, 0.007271698676049709, -0.1552896797657013, 0.055092256516218185, -0.15894156694412231, 0.12850360572338104, 0.09701618552207947, 0.016765505075454712, -0.18474777042865753, -0.08420147001743317, -0.004707424435764551, -0.032402969896793365, 0.0027001507114619017, 0.08817620575428009, 0.06397825479507446, 0.0461396649479866, -0.0100649269297719, 0.00418752059340477, -0.10049179196357727, -0.07422086596488953, 0.0842152088880539, -0.03227805718779564, -0.09063180536031723, 0.08916939049959183, 0.04887331277132034, -0.03163228929042816, -1.0034376884959784e-07, 0.013060616329312325, -0.04556232690811157, -0.006749847903847694, -0.08016537874937057, 0.0744093507528305, -0.13548626005649567, -0.011967116966843605, -0.10248516499996185, 0.07981034368276596, 0.19208067655563354, 0.06672275811433792, 0.0626615509390831, -0.11407055705785751, -0.04257296025753021, -0.17566132545471191, 0.06542001664638519, -0.05018393695354462, 0.007305401377379894, -0.07831260561943054, -0.05398627370595932, -0.11155387759208679, 0.004711967892944813, -0.0839497447013855, -0.03076530247926712, 0.0586836114525795, -0.003907265141606331, 0.0947360247373581, 0.02778335101902485, -0.0015301251551136374, 0.07206778228282928, 0.012014534324407578, 0.04532117024064064, 0.12666326761245728, 0.04509983956813812, -0.035141509026288986, -0.10992021858692169, 0.11403170228004456, 0.0901041105389595, -0.03629694879055023, 0.15509161353111267, -0.011534484103322029, 0.05498044565320015, 0.004265777766704559, 0.07495927810668945, 0.11079913377761841, -0.005959823727607727, -0.17981845140457153, 0.05643738806247711, 0.035926468670368195, -0.08761204779148102, 0.08564223349094391, 0.03858811408281326, -0.06259587407112122, -0.00984919536858797, -0.12328898906707764, 0.03543559089303017, -0.011517214588820934, 0.07085298001766205, -0.007619267329573631, -0.06120895594358444, 0.1605539172887802, -0.11012345552444458, 0.08705063909292221, 0.07714755088090897], "changes": {"1wk": 13.793103920766105, "1mo": 12.528731836512272}}, {"text": "Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference ACCESS Newswire \u00b7 Biofrontera Inc. Biofrontera Inc. Tue, Dec 3, 2024, 7:00 PM 4 min read In This Article: BFRI BFRIW WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\") , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will be presenting at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic Club in New York City. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Biofrontera will be participating in one-on-one meetings with investors and analysts throughout the day. To schedule a one-on-one meeting with Biofrontera, you may submit your request online via the registration link provided. To register for the conference, please visit https://www.meetmax.com/sched/event_112571/investor_reg_new.html?attendee_role_id=INVESTOR About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz \u00ae with the RhodoLED \u00ae lamp series for PDT of Actinic Keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers 1 . The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X . 1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/ About The Benchmark Company The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. It was founded in 1988 and are headquartered in New York City. Its focus is on fostering the long-term success of corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading, and equity research capabilities. https://www.benchmarkcompany.com . Contacts Investor Relations Andrew Barwicki 1-516-662-9461 ir@bfri.com Forward-Looking Statements Certain statements in this press release may constitute \"forward-looking statements\" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's revenue guidance, business and marketing strategy, revenue growth, sales force productivity, growth strategy, liquidity and cash flow, potential to expand the label of Ameluz\u00ae, available market opportunities for Ameluz\u00ae, ongoing clinical trials, educational outreach efforts, and other statements that are not historical facts. The words \"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\" \"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\", \"target\", \"goal\", \"assume\", \"would\", \"could\" or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events; nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, our reliance on sales of products we license from other companies as our sole source of revenue; the success of our competitors in developing generic topical dermatological products that successfully compete with our licensed products; the success of our principal licensed product, Ameluz\u00ae; the ability of the Company's licensors to establish and maintain relationships with contract manufacturers that are able to supply the Company with enough of the licensed products to meet our demand; the ability of our licensors or their manufacturing partners to supply the licensed products that we market in sufficient quantities and at acceptable quality and cost levels, and to fully comply with current good manufacturing practice or other applicable manufacturing regulations; the ability of our licensors to successfully defend or enforce patents related to our licensed products; the availability of insurance coverage and medical expense reimbursement for our licensed products; the impact of legislative and regulatory changes; competition from other pharmaceutical and medical device companies and existing treatments, such as simple curettage and cryotherapy; the Company's ability to achieve and sustain profitability; the Company's ability to obtain additional financing as needed to implement its growth strategy; the Company's ability to retain and hire key personnel; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission (\"SEC\"), which can be obtained on the SEC website at www.sec.gov . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not undertake to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release, except as required by law. SOURCE: Biofrontera Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-12-03T19:00:00", "sentiment": {"score": 0.05262899771332741, "confidence": 0.06332382559776306, "probabilities": {"positive": 0.06332382559776306, "negative": 0.010694827884435654, "neutral": 0.9259814023971558}}, "embedding": [-0.09872540831565857, -0.13201674818992615, -0.14244812726974487, -0.033748872578144073, 0.04349815472960472, -0.08338911831378937, -0.08985322713851929, 0.1828806847333908, 0.07716476917266846, 0.04663924127817154, -0.10811202973127365, -0.024873733520507812, -0.037620365619659424, 0.03537236899137497, -0.08188867568969727, -0.015352342277765274, 0.03955629840493202, -0.054173775017261505, 0.06071758270263672, 0.05397404730319977, -0.1077951192855835, -0.037375397980213165, 0.1135353371500969, 0.03162936493754387, -0.020354293286800385, -0.019981127232313156, -0.1589249223470688, -0.09002318978309631, -0.19981858134269714, -0.08555193245410919, 0.13236045837402344, 0.033440690487623215, 0.07054319977760315, -0.018385224044322968, 0.06394118070602417, 0.00711064413189888, -0.0800086259841919, 0.07452832162380219, -0.08418209850788116, 0.04947991669178009, -0.07313069701194763, -0.10183461010456085, -0.11898136138916016, -0.022799646481871605, 0.0961344763636589, -0.1393241584300995, -0.08276571333408356, 0.09385688602924347, 0.0659254714846611, 0.09941574931144714, -0.13019418716430664, -0.16172200441360474, -0.02714190073311329, 0.03902515023946762, -0.09025610238313675, 0.06625717133283615, -0.07844223082065582, 0.010064734145998955, -0.03746839985251427, 0.01220928505063057, 0.07560863345861435, -0.14055250585079193, -0.006825998425483704, 0.025665564462542534, 0.2303723692893982, 0.025106536224484444, 0.004466582089662552, -0.01188565418124199, 0.05517174303531647, -0.11373375356197357, 0.0622733049094677, -0.09477803111076355, 0.0021224245429039, 0.1336236149072647, -0.029463443905115128, 0.19905494153499603, 0.10343310981988907, 0.15562374889850616, 0.1822720319032669, -0.08036433905363083, 0.13127586245536804, 0.08073388040065765, 0.00455523282289505, -0.07256399840116501, -0.004497008863836527, 0.027621164917945862, -0.027096107602119446, 0.10355375707149506, 0.09329875558614731, 0.023461205884814262, 0.024622570723295212, 0.040115274488925934, -0.06267695128917694, -0.0392138808965683, -0.07148139178752899, -0.06052213907241821, -0.06267783045768738, 0.041621699929237366, 0.05792999267578125, 0.0030677150934934616, -0.007792007643729448, -0.07909528911113739, -0.1439603716135025, 0.05914465710520744, -0.17572438716888428, -0.11090688407421112, -0.011519678868353367, -0.057261914014816284, 0.12523479759693146, 0.03556458652019501, -0.05720501020550728, 0.06077318638563156, 0.0335392989218235, -0.030774185433983803, -0.06707341223955154, 0.1493234634399414, -0.07580656558275223, 0.006212584208697081, 0.24705378711223602, -0.13759863376617432, -0.051245469599962234, -0.029951509088277817, 0.0781448483467102, -0.15659403800964355, 0.03659636899828911, -0.02150905318558216, -0.10111844539642334, 4.534487825396206e-33, 0.022456474602222443, 0.0778152272105217, 0.03718016296625137, 0.012539766728878021, -0.1296052634716034, -0.04185188561677933, -0.00852432195097208, -0.08937729150056839, -0.1644074022769928, -0.08224911987781525, -0.08951658010482788, 0.1332058161497116, -0.0017618630081415176, 0.1364549845457077, -0.07345500588417053, -0.06096354126930237, 0.06696898490190506, -0.004352109506726265, 0.029144346714019775, -0.13036242127418518, 0.009223004803061485, 0.1104002594947815, -0.09614438563585281, 0.039602529257535934, -0.04095824435353279, 0.05248493701219559, -0.14047588407993317, 0.092002734541893, -0.005323557183146477, 0.07248005270957947, -0.1161021739244461, 0.06069273501634598, -0.05070667341351509, -0.05775807425379753, -0.051734790205955505, -0.06194288656115532, -0.014139121398329735, -0.14758315682411194, 0.052138552069664, 0.05373084917664528, -0.08936896175146103, 0.12530824542045593, -0.02712080255150795, -0.10816247761249542, 0.04089310020208359, 0.00470536295324564, -0.14228455722332, 0.05678851902484894, 0.09425953030586243, 0.028331954032182693, -0.08609622716903687, -0.018705900758504868, 0.022828035056591034, -0.04941403865814209, -0.01747306063771248, 0.0204850472509861, -0.17768937349319458, -0.16340883076190948, 0.12890100479125977, 0.18779465556144714, 0.03656980022788048, 0.10216489434242249, -0.14050571620464325, 0.02977673150599003, -0.25511255860328674, 0.0016184058040380478, 0.0846865251660347, 0.09205079078674316, -0.005591674707829952, 0.1266651451587677, 0.008132552728056908, 0.0978488028049469, 0.22335076332092285, -0.02348523773252964, 0.1810871958732605, -0.0684325248003006, 0.1175663024187088, 0.20326292514801025, -0.11798470467329025, 0.04502337425947189, -0.08674634993076324, 0.1011873334646225, -0.030105866491794586, 0.09073704481124878, -0.032667890191078186, 0.03683288022875786, 0.020501304417848587, 0.04476088657975197, -0.1821383535861969, -0.04371965676546097, 0.04184985160827637, -0.09457823634147644, -0.07199236750602722, 0.21246488392353058, -0.05299745500087738, -6.0303212845488596e-33, 0.04037340357899666, -0.08683839440345764, 0.01812104694545269, -0.10452815890312195, 0.06524791568517685, 0.11797496676445007, 0.0955064445734024, -0.028934674337506294, 0.01732376590371132, -0.02020225301384926, 0.021513424813747406, 0.03715521842241287, -0.018852269276976585, -0.10086613148450851, 0.009666366502642632, -0.027623439207673073, -0.024292651563882828, -0.12382113188505173, -0.14369380474090576, 0.06725846230983734, 0.09342367947101593, 0.09816034138202667, -0.0916283130645752, 0.008108624257147312, -0.031954482197761536, -0.00924455001950264, 0.04822995141148567, 0.06636665761470795, 0.02731383591890335, -0.09842406958341599, -0.03234799951314926, 0.07206456363201141, -0.21050164103507996, 0.06540390849113464, 0.015947803854942322, 0.0915413647890091, 0.05325450003147125, -0.17815706133842468, -0.043561868369579315, -0.03834591805934906, 0.11267155408859253, 0.0628780871629715, -0.14046093821525574, 0.0006342828273773193, 0.11193212866783142, 0.07296427339315414, -0.07718773186206818, -0.0012687332928180695, 0.11260144412517548, 0.03737112134695053, -0.04947350174188614, 0.05054354667663574, 0.045439932495355606, -0.01792566478252411, 0.005770803429186344, -0.008939382620155811, 0.045951470732688904, 0.027379808947443962, -0.1312645822763443, 0.1874893605709076, 0.105614572763443, 0.023372406139969826, -0.04336955398321152, 0.11755737662315369, 0.07399134337902069, 0.06113821268081665, 0.05988290160894394, 0.022961992770433426, -0.01171546708792448, 0.059520475566387177, 0.004702806007117033, -0.015502708964049816, 0.0038744169287383556, -0.046334270387887955, 0.0011998163536190987, 0.03188527375459671, -0.0020391312427818775, -0.08936713635921478, -0.1206229105591774, 0.0017732330597937107, -0.022328896448016167, -0.05976884067058563, 0.03712863475084305, 0.04209977760910988, 0.14104464650154114, 0.1802881956100464, 0.024152830243110657, 0.0027036406099796295, -0.07212243229150772, 0.09808047115802765, -0.03390948474407196, -0.08487734943628311, -0.028387535363435745, 0.10254731774330139, 0.0390365906059742, -9.989190630221856e-08, 0.1310245394706726, -0.09027421474456787, 0.08151496946811676, -0.1377905011177063, -0.022755302488803864, 0.011368375271558762, -0.02005302533507347, 0.014774573035538197, 0.06747039407491684, 0.06919410824775696, -0.01307694986462593, 0.0985623225569725, -0.11180545389652252, 0.024663062766194344, -0.13045421242713928, 0.02699022740125656, -0.091349758207798, 0.06797146797180176, -0.06357616186141968, -0.027726121246814728, -0.08343099802732468, 0.015548011288046837, 0.07006116956472397, -0.14925891160964966, 0.03720510005950928, -0.06747154891490936, -0.017324183136224747, 0.05281040817499161, -0.0003857724368572235, -0.057665884494781494, -0.011786195449531078, 0.018925804644823074, 0.10891541838645935, 0.024221329018473625, 0.05373932421207428, -0.09889595210552216, 0.04078160226345062, 0.12306010723114014, -0.01906059868633747, 0.19807492196559906, -0.044405072927474976, 0.02667194977402687, 0.01372058317065239, -0.0019594132900238037, 0.035186007618904114, 0.04027191549539566, -0.15424828231334686, -0.0034040408208966255, 0.06678617745637894, -0.09167294204235077, -0.048685960471630096, -0.06469076126813889, -0.04106881469488144, -0.09113723039627075, -0.07227736711502075, 0.1112414002418518, -0.031168479472398758, -0.06114720553159714, 0.053388744592666626, -0.012163827195763588, 0.21092753112316132, -0.20076465606689453, 0.044524166733026505, 0.18311728537082672], "changes": {"1wk": 27.136759674961098, "1mo": 16.452996324252837}}, {"text": "PREMIUM Sector Update: Health Care Stocks Edge Higher Late Afternoon MT Newswires Fri, Nov 22, 2024, 11:45 PM 1 min read Sector Update: Health Care Stocks Edge Higher Late Afternoon PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-22T23:45:29", "sentiment": {"score": 0.07504978403449059, "confidence": 0.08761650323867798, "probabilities": {"positive": 0.08761650323867798, "negative": 0.012566719204187393, "neutral": 0.8998167514801025}}, "embedding": [-0.08875442296266556, -0.08927716314792633, 0.04019051790237427, 0.12012650072574615, 0.1846598982810974, -0.04073626175522804, -0.09902931749820709, 0.01785709150135517, -0.09954848885536194, 0.008135491982102394, -0.0029946391005069017, 0.1731872707605362, -0.0437748096883297, -0.061978619545698166, 0.1790151596069336, -0.05805934593081474, 0.10823582112789154, -0.058469150215387344, -0.11149649322032928, 0.08272570371627808, -0.1523910015821457, -0.06260782480239868, 0.06252863258123398, -0.01336490549147129, 0.09421910345554352, 0.06995204091072083, -0.10000568628311157, -0.030828172340989113, -0.03124391660094261, 0.018856653943657875, 0.0220689345151186, -0.04545174911618233, 0.10049441456794739, 0.004205698147416115, -0.03255372494459152, -0.06944815814495087, -0.0008672274998389184, 0.104023277759552, -0.05106951668858528, 0.06704093515872955, 0.07655810564756393, -0.2147858589887619, -0.07695597410202026, 0.010043204762041569, 0.08687277883291245, -0.006695923395454884, -0.08552103489637375, -0.0633026510477066, 0.0765433982014656, 0.10208076238632202, -0.062402863055467606, -0.10182055085897446, 0.023514343425631523, -0.033467330038547516, -0.04170599952340126, -0.010920721106231213, -0.16664616763591766, -0.1398257166147232, -0.10215825587511063, -0.005049184430390596, -0.0969076082110405, -0.10906725376844406, 0.003758687060326338, 0.09496437758207321, -0.08698417991399765, 0.12072587013244629, 0.08615368604660034, 0.23362287878990173, -0.04620516300201416, -0.19889689981937408, 0.045335203409194946, -0.04612996429204941, 0.012852589599788189, 0.027601558715105057, 0.1407146453857422, 0.09302268177270889, 0.1214202418923378, 0.0013507320545613766, 0.09626561403274536, -0.13097165524959564, 0.02137746475636959, -0.0831621065735817, -0.036166056990623474, 0.11681649833917618, -0.05604991316795349, -0.02389143593609333, -0.025932759046554565, -0.14431287348270416, -0.0862271785736084, -0.23060034215450287, 0.13051098585128784, 0.03213416039943695, -0.03028147481381893, 0.06906598806381226, 0.1077965721487999, 0.008422216400504112, -0.22534096240997314, -0.21601861715316772, -0.19295068085193634, 0.027632109820842743, -0.00815906934440136, -0.07604736089706421, -0.02638617344200611, 0.08429548889398575, 0.031864412128925323, -0.18049581348896027, -0.18078309297561646, 0.19594724476337433, 0.0651436299085617, 0.07129395008087158, 0.11350222676992416, 0.12115398049354553, 0.06003459170460701, -0.15678152441978455, -0.11647935956716537, 0.03958945348858833, -0.09029886871576309, -0.15646304190158844, 0.12395242601633072, 0.10565468668937683, 0.04714270308613777, 0.045654039829969406, -0.2410450577735901, -0.0634661614894867, 0.08121494948863983, 0.02456309087574482, 0.08016632497310638, 1.4434988343493133e-32, 0.06097009778022766, 0.10753338038921356, 0.14904308319091797, -0.13723506033420563, 0.06343946605920792, 0.06708827614784241, 0.028599128127098083, -0.22714978456497192, -0.006705740932375193, -0.03896019980311394, -0.24696072936058044, 0.2537771165370941, 0.0054387724958360195, -0.0578208826482296, -0.1628994196653366, -0.24366524815559387, -0.08078086376190186, 0.1212279200553894, 0.016011428087949753, 0.13125137984752655, -0.05164291709661484, -0.10505839437246323, -0.10539055615663528, -0.055581022053956985, -0.10796647518873215, 0.1180514395236969, 0.06892358511686325, -0.15339723229408264, 0.16704732179641724, 0.12357234954833984, -0.09056582301855087, 0.07184705883264542, -0.008673835545778275, -0.11685894429683685, 0.05904168263077736, 0.19756244122982025, -0.031496964395046234, -0.04199112206697464, -0.024154527112841606, -0.2342344969511032, -0.10779429972171783, -0.05833107605576515, -0.05575067177414894, 0.012389746494591236, 0.05899301916360855, 0.057586535811424255, 0.03772339969873428, -0.13166716694831848, 0.009225969202816486, -0.09817904233932495, -0.06013110652565956, 0.08510798215866089, -0.11812858283519745, -0.020073886960744858, -0.0029126780573278666, -0.05658506602048874, -0.03652597591280937, -0.0036879763938486576, -0.007819658145308495, 0.026833662763237953, 0.23825708031654358, -0.012072242796421051, 0.006605752278119326, -0.08350419253110886, -0.17740197479724884, 0.05622041970491409, -0.09615302085876465, -0.015295671299099922, -0.038217466324567795, 0.13641321659088135, 0.18179906904697418, 0.05991378426551819, -0.01395632978528738, 0.05844039469957352, -0.07927048951387405, 0.1282171905040741, -0.11617513000965118, 0.09949163347482681, 0.10799582302570343, 0.02995700016617775, 0.0759364441037178, 0.0035673296079039574, 0.07293575257062912, 0.029311448335647583, 0.16266590356826782, 0.10530857741832733, 0.009478763677179813, -0.015464254654943943, -0.07068093121051788, -0.07186617702245712, -0.21147117018699646, 0.10565899312496185, 0.15855567157268524, 0.21763162314891815, -0.022170811891555786, -1.7811457745643932e-32, -0.04169057682156563, 0.039593394845724106, 0.009505023248493671, 0.018090013414621353, 0.01393831055611372, -0.08516021072864532, 0.021164128556847572, 0.0796249583363533, 0.12700127065181732, 0.18770329654216766, 0.0814741775393486, 0.10182278603315353, -0.0744713842868805, 0.043121278285980225, 0.07177378982305527, -0.02757207490503788, -0.03763654828071594, -0.06914368271827698, -0.06356198340654373, 0.12421363592147827, -0.010459160432219505, 0.023205960169434547, -0.13496972620487213, 0.32877108454704285, 0.1400870382785797, 0.05119452252984047, -0.04706438630819321, 0.1534939706325531, 0.17521372437477112, -0.19826366007328033, -0.17824377119541168, -0.027829129248857498, -0.11370597034692764, -0.02794196642935276, -0.08493279665708542, 0.0011037132935598493, 0.1238945946097374, -0.06491261720657349, -0.07529650628566742, -0.037417441606521606, 0.1623302400112152, -0.21818117797374725, -0.04030584543943405, 0.07014504075050354, 0.1036396324634552, 0.08187835663557053, -0.018824618309736252, 0.10665703564882278, -0.04431838169693947, -0.01115916296839714, -0.09191011637449265, 0.11483603715896606, 0.05421827733516693, 0.23590905964374542, -0.14267991483211517, 0.0720212459564209, -0.03274432569742203, -0.04072844982147217, -0.15030162036418915, -0.11265607178211212, 0.06806740164756775, 0.10509447753429413, -0.29205384850502014, -0.028516659513115883, -0.01745171658694744, -0.01415220182389021, 0.14836792647838593, -0.21639001369476318, -0.052879080176353455, -0.009712420403957367, -0.16430963575839996, -0.07991425693035126, -0.18637749552726746, -0.31351423263549805, 0.027178030461072922, 0.17345012724399567, 0.059833426028490067, 0.007329544518142939, -0.13092884421348572, 0.13155625760555267, 0.05044553428888321, -0.14135663211345673, -0.00436018779873848, -0.011232953518629074, -0.10761994868516922, 0.04476417973637581, 0.1165112555027008, -0.16770212352275848, -0.17919161915779114, 0.003400793531909585, -0.3072313368320465, -0.1981651932001114, -0.2363721877336502, 0.09797213226556778, -0.04947558790445328, -1.0085349089195006e-07, 0.1253722608089447, 0.02884850837290287, 0.008723276667296886, -0.06312718242406845, 0.09071707725524902, -0.0742986723780632, -0.1275036484003067, 0.06419526785612106, 0.05291075259447098, 0.22714516520500183, 0.017942655831575394, 0.059905100613832474, -0.09561795741319656, -0.08542542159557343, 0.047393590211868286, -0.03275606408715248, -0.11150161921977997, 0.07232878357172012, 0.04342079535126686, -0.09600461274385452, 0.0825386717915535, 0.009546064771711826, 0.19054462015628815, -0.10462134331464767, -0.0055605573579669, 0.07448232918977737, -0.05989549309015274, -0.04219694435596466, 0.10474978387355804, 0.10580750554800034, -0.03268173709511757, 0.012791825458407402, 0.007617441471666098, -0.06950893253087997, 0.0460796132683754, 0.002136696595698595, 0.08736012876033783, -0.003208928508684039, 0.0939633846282959, 0.018679087981581688, 0.15369300544261932, -0.10362333804368973, 0.06994964927434921, 0.06382254511117935, 0.01277150772511959, -0.04825352132320404, 0.04404120892286301, -0.01883601024746895, 0.15503723919391632, -0.14879001677036285, 0.032095249742269516, -0.14807069301605225, 0.14124377071857452, -0.048357900232076645, -0.04864567145705223, 0.08374251425266266, 0.001980469562113285, -0.11864934116601944, -0.16669504344463348, 0.24160513281822205, 0.1568537950515747, -0.2601296007633209, -0.0045615071430802345, 0.173906147480011], "changes": {"1wk": 3.448272554637248, "1mo": 12.528731836512272}}, {"text": "Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates Zacks Equity Research Tue, Nov 12, 2024, 5:30 PM 3 min read In This Article: OVID Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced earnings of $0.12, delivering a surprise of 154.55%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Ovid Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.17 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 15.33%. This compares to year-ago revenues of $0.11 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Ovid Therapeutics shares have lost about 57.8% since the beginning of the year versus the S&P 500's gain of 25.8%. What's Next for Ovid Therapeutics? While Ovid Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Ovid Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $0.16 million in revenues for the coming quarter and -$0.49 on $0.56 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Biofrontera Inc. (BFRI), has yet to report results for the quarter ended September 2024. The results are expected to be released on November 13. This company is expected to post quarterly loss of $0.73 per share in its upcoming report, which represents a year-over-year change of +84.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Biofrontera Inc.'s revenues are expected to be $11.01 million, up 23.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ovid Therapeutics (OVID) : Free Stock Analysis Report Biofrontera Inc. (BFRI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-12T17:30:02", "sentiment": {"score": -0.42845307290554047, "confidence": 0.5521095395088196, "probabilities": {"positive": 0.12365646660327911, "negative": 0.5521095395088196, "neutral": 0.3242339789867401}}, "embedding": [-0.1263318955898285, -0.005420977249741554, -0.018990371376276016, 0.1044146791100502, 0.009234372526407242, -0.08243177831172943, -0.028225770220160484, 0.20920556783676147, 0.28862008452415466, 0.08775730431079865, -0.1671229600906372, 0.1865319013595581, -0.04011685401201248, -0.00909379031509161, -0.12301528453826904, 0.07418174296617508, 0.09349307417869568, 0.006308417767286301, -0.08622381091117859, 0.07530763745307922, -0.07280971109867096, -0.028280025348067284, 0.1827557384967804, 0.0677555501461029, 0.08212888985872269, 0.009576027281582355, -0.15010817348957062, 0.08891897648572922, -0.11893865466117859, -0.15444126725196838, 0.01083187386393547, 0.11484085768461227, 0.13125433027744293, -0.11841484159231186, -0.0717889815568924, -0.0922309011220932, 0.054095011204481125, 0.03612559661269188, -0.03517868369817734, 0.018312066793441772, -0.054251961410045624, 0.05478540062904358, -0.16490420699119568, 0.07570086419582367, -0.027881920337677002, -0.22482019662857056, -0.05106111615896225, -0.002427578903734684, 0.012102955020964146, 0.13595736026763916, -0.19554254412651062, -0.14427393674850464, -0.026564784348011017, 0.05179883912205696, -0.13962507247924805, 0.03684614226222038, -0.16747096180915833, -0.12061254680156708, 0.06505173444747925, 0.10538379848003387, 0.03361757472157478, 0.06517805904150009, 0.05043429881334305, 0.10423244535923004, 0.15940271317958832, -0.012165818363428116, 0.10987398773431778, 0.0498712956905365, -0.12311191856861115, 0.09503244608640671, 0.10907222330570221, -0.03661338612437248, -0.04031610116362572, -0.00488702580332756, -0.14347192645072937, 0.06691204756498337, 0.12342401593923569, 0.1322062909603119, 0.1112109124660492, 0.0023704415652900934, 0.04670514166355133, -0.0637390986084938, -0.08235344290733337, -0.02361123263835907, -0.009997934103012085, -0.017486069351434708, 0.13558810949325562, 0.15310952067375183, 0.05135229229927063, 0.020536471158266068, -0.09689871966838837, -0.08078250288963318, 0.03360211104154587, -0.061044108122587204, 0.07463525235652924, -0.0005139205604791641, -0.00870570633560419, -0.12766514718532562, 0.04871313273906708, 0.06786314398050308, 0.05005104839801788, 0.046334899961948395, -0.03438757732510567, -0.10493258386850357, 0.029910976067185402, -0.12101319432258606, 0.0769081562757492, -0.008103137835860252, -0.004391427151858807, 0.0884469598531723, 0.002420317381620407, 0.08248709887266159, -0.1374378204345703, -0.057491790503263474, -0.06479527801275253, 0.14110225439071655, -0.09404287487268448, 0.10046383738517761, 0.06287994235754013, 0.1728707253932953, 0.02613048069179058, 0.03284855931997299, -0.0321369506418705, 0.023111477494239807, 0.006151927635073662, 0.0860431045293808, -0.09813924133777618, 8.108333014625637e-33, 0.13435202836990356, 0.04370284080505371, 0.05551418662071228, -0.07103091478347778, -0.007567590568214655, 0.0371488481760025, 0.13303598761558533, -0.020727280527353287, -0.044337768107652664, -0.08465774357318878, -0.16368678212165833, 0.07611265778541565, 0.012811277061700821, -0.015742387622594833, 0.03488808125257492, -0.1759503036737442, -0.04568307101726532, 0.04556640610098839, -0.027813216671347618, 0.006671544164419174, 0.05117332562804222, -0.02320464886724949, -0.052055321633815765, 0.13576740026474, 0.009129622019827366, 0.061193808913230896, -0.19117827713489532, 0.007680380716919899, -0.10588285326957703, 0.035885781049728394, -0.028447099030017853, 0.002765626646578312, 0.08039692044258118, -0.18883898854255676, -0.061477381736040115, -0.09201221168041229, -0.05806933715939522, -0.03653322532773018, 0.24360503256320953, 0.045989956706762314, -0.05552550032734871, 0.0956716239452362, -0.15168467164039612, -0.17851325869560242, -0.05637618154287338, 0.037716493010520935, -0.06870099902153015, -0.009869668632745743, -0.07379624247550964, -0.012658917345106602, -0.041752588003873825, 0.02335812896490097, -0.05920690298080444, -0.00255496334284544, -0.0552297979593277, -0.0022415630519390106, -0.17299488186836243, -0.13894110918045044, 0.05230633169412613, 0.1297266036272049, 0.13594472408294678, 0.22037789225578308, 0.06140327453613281, -0.07598012685775757, -0.2933042049407959, 0.13666637241840363, 0.0807720273733139, 0.02755703218281269, -0.13702555000782013, 0.21833863854408264, -0.03836466372013092, -0.005292792338877916, 0.0183443333953619, -0.08328266441822052, 0.21881794929504395, -0.055943820625543594, -0.02617320418357849, -0.051771678030490875, 0.11118144541978836, 0.005845367908477783, 0.0688619464635849, -0.021221622824668884, 0.0074686529114842415, 0.08243631571531296, 0.02091631293296814, -0.025644585490226746, 0.022220151498913765, 0.11067713797092438, -0.08525511622428894, 0.016751382499933243, -0.006722270045429468, -0.12181635200977325, -0.007819400168955326, 0.09001928567886353, 0.03284226357936859, -8.252214257850254e-33, -0.0343339778482914, 0.06869254261255264, 0.035257820039987564, -0.06148284673690796, -0.09292002022266388, 0.034907929599285126, 0.046674177050590515, 0.1159491017460823, 0.05341627448797226, -0.02124127373099327, -0.00797964259982109, 0.08403950929641724, -0.16086441278457642, 0.07039645314216614, -0.12479877471923828, -0.04797426611185074, 0.013222841545939445, -0.10037584602832794, 0.02940966747701168, -0.040911316871643066, -0.02478579245507717, 0.1851457804441452, -0.033868495374917984, 0.04972454532980919, 0.11187724769115448, 0.10974171757698059, 0.05748813599348068, 0.05421625077724457, 0.028628656640648842, -0.04455956071615219, -0.020722873508930206, -0.0715000331401825, -0.17835325002670288, 0.057695478200912476, 0.04458880424499512, -0.021132640540599823, 0.029941629618406296, -0.18354912102222443, -0.06902462244033813, -0.07011270523071289, 0.1511930525302887, -0.015203949995338917, 0.06157933175563812, 0.0021234191954135895, 0.06840193271636963, 0.08554000407457352, -0.004900284111499786, 0.060584019869565964, 0.2320624440908432, 0.036101505160331726, 0.010968215763568878, 0.00880538858473301, -0.10733248293399811, 0.16584886610507965, -0.1204855740070343, -0.05051000416278839, -0.07007943838834763, -0.08372984826564789, -0.16784948110580444, -0.04338172450661659, -0.01622948795557022, 0.10297992825508118, 0.009334162808954716, 0.03309662267565727, 0.023834722116589546, 0.11350637674331665, 0.09873266518115997, -0.03562745824456215, -0.004522255621850491, -0.16454744338989258, -0.025174742564558983, -0.10916385054588318, 0.036909423768520355, -0.13525761663913727, 0.0466790534555912, 0.2916046380996704, -0.04591677337884903, -0.22288766503334045, -0.07826178520917892, -0.0015177871100604534, 0.03556007891893387, -0.03536377474665642, 0.047959476709365845, -0.008961912244558334, -0.1276559978723526, 0.1551399827003479, 0.057270899415016174, -0.03446749225258827, 0.037327855825424194, 0.07661206275224686, -0.09823343902826309, -0.2042911946773529, -0.12638437747955322, 0.009479941800236702, 0.10689318180084229, -9.985173932136604e-08, 0.07858915627002716, -0.09864506125450134, 0.059475429356098175, 0.02312752977013588, 0.07155949622392654, -0.0074010868556797504, 0.007686714641749859, 0.002255380153656006, 0.14223988354206085, 0.17567652463912964, 0.11374779045581818, 0.08701540529727936, -0.17109990119934082, -0.022033046931028366, -0.14263084530830383, 0.05927282199263573, -0.0899055227637291, 0.060724109411239624, -0.00046318769454956055, -0.1548198163509369, -0.16557766497135162, 0.07387912273406982, 0.1706225574016571, -0.07808830589056015, 0.05437200888991356, -0.08577603101730347, -0.06784563511610031, -0.06408822536468506, 0.04208644852042198, -0.036967597901821136, 0.10460901260375977, -0.04171600937843323, 0.07712315022945404, 0.09699075669050217, -0.08390112221240997, -0.2175137996673584, 0.10201925784349442, 0.09021501243114471, 0.07623042166233063, 0.08723680675029755, -0.01817314885556698, -0.0011465419083833694, 0.01555863581597805, 0.012563662603497505, -0.017203137278556824, -0.050721485167741776, -0.08221589028835297, 0.0039925663731992245, -0.04469049721956253, -0.2669321894645691, 0.1123618483543396, -0.08624555170536041, -0.016533320769667625, 0.01863340474665165, -0.02794811502099037, -0.0009953062981367111, -0.1940997838973999, -0.06285708397626877, -0.20305116474628448, -0.12629520893096924, 0.06291323900222778, -0.23298048973083496, 0.13490043580532074, 0.10665687918663025], "changes": {"1wk": -18.36517868707415, "1mo": 12.52653656444512}}, {"text": "Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update Biofrontera Inc. Thu, Nov 14, 2024, 1:15 AM 13 min read In This Article: BFRI BFRIW Biofrontera Inc. \u25cf Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. \u25cf Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. \u25cf Ameluz\u00ae achieved record volume in September 2024. \u25cf Organization continues to prudently manage SG&A expenses in line with business needs with a reduction of 14% in the first 9 months of 2024 vs 2023. \u25cf Cash and cash equivalents were $2.9 million as of September 30, 2024, compared with $1.3 million on December 31, 2023. \u25cf RhodoLED XL launch continues to be successful with 39 installed since launch in late June 2024; additionally, 66 BF-RhodoLED lamps have been installed in the first three quarters of 2024. \u25cf On October 4 FDA approved sNDA to increase the maximally allowed dosage of Ameluz\u00ae from one tube to three tubes per treatment. \u25cf Preliminary results of Phase 3 sBCC study are highly statistically significant for all primary and secondary endpoints (p<0.0001). Ameluz-PDT achieved 75.9% histological clearance vs 19% with placebo. WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated, \u201cWhile we are pleased with the third quarter results, we faced challenges from Hurricane Milton that impacted our business and that of our customers in the areas affected. The hurricane delayed the shipment of 4,640 tubes of Ameluz, representing approximately $1.5 million in revenue. All the tubes were shipped in October and will count towards Q4. As reported, this reduced our quarterly growth to 1.5% and year-to-date growth to 5.6%. Without this delay, quarterly growth would have been 19% and year-to-date growth 12%.\u201d \u201cWe have made some important progress across our business in 2024. We have seen very positive uptake of our products throughout the United States, illustrated by the number of lamps sold to dermatology offices. The transfer of clinical trial activities from Biofrontera AG to Biofrontera Inc. was seamless, with all trials progressing as planned. We continue to prepare our FDA filing for the approval of Ameluz for the treatment of sBCC, which we expect to submit in the 1 st half of 2025. If that is the case, we anticipate approval in early 2026. Furthermore, on October 4 th the FDA approved an increase in the maximally approved dosage from one to three tubes of Ameluz \u00ae per treatment. This approval allows for larger field treatment of mild to moderate actinic keratosis on the face and scalp with Ameluz\u00ae-PDT using the BF-RhodoLED \u00ae or the RhodoLED \u00ae XL lamp. Based on the extended approval\u00a0\u00a0 we are rapidly implementing a comprehensive update to our commercial strategy that we believe will drive significant sales growth in the coming years,\u201d concluded Prof. Luebbert. Story Continues Third Quarter Financial Results Total revenues for the third quarter of 2024 were $9.0 million compared with $8.9 million for the third quarter of 2023. This increase was driven by a $0.6 million increase from sales of devices, offset by a net decrease in sales of Ameluz of $0.5 million. The decline in Ameluz unit sales resulted from the delayed delivery of 4,640 units in October 2024, as Hurricane Milton caused office closures and shipping delays across the Southeast. Total operating expenses were $14.0 million for the third quarter of 2024 compared with $13.5 million for the third quarter of 2023. Cost of revenues was $4.9 million for the third quarter of 2024 compared with $4.6 million for the prior-year quarter. This was driven by an increase of $0.5 million due to higher COGS for lamp revenue, partially offset by a decrease of $0.2 million due to the decrease in sales of Ameluz \u00ae . Selling, general and administrative expenses were $8.4 million for the third quarter of 2024 compared with $8.6 million for the third quarter of 2023. The decrease was primarily driven by a $0.5 million reduction in general business administration expenses, as well as a decrease of non-personnel sales and marketing expenses of $0.2 million, and a $0.3 million decrease in personnel costs due to change in headcount and reduced severance. This was offset by a $0.8 million increase in legal expenses related to the competitor complaints at the International Trade Commission (ITC) and the US District Court for the District of Massachusetts. The net loss for the third quarter of 2024 was $5.7 million, compared with a net loss of $6.3 million for the prior-year quarter. Adjusted EBITDA for the third quarter of 2024 was negative $4.6 million compared with negative $3.9 million for the third quarter of 2023, reflecting our selling, general, and administrative costs. We look at Adjusted EBITDA, a non-GAAP financial measure, as a better indication of ongoing operations and this measurement is defined as net income or loss excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items. The primary driver of the lower Adjusted EBITDA was increased R&D spend since we took over clinical operations for Ameluz as of June 2024. Please refer to the table below which presents a GAAP to non-GAAP reconciliation of Adjusted EBITDA for the third quarters of 2024 and 2023. Nine Month Financial Results Total YTD revenues were $24.7, an increase of $1.3 million, or 5.6% as compared to the same period last year. This increase was driven by a higher unit sales price for Ameluz \u00ae and a revenue increase in device sales due to the commercial launch of the RhodoLED XL. After a revenue decline of 9% in Q1 followed by 8% growth for the first half of the year, we would now have seen year-over-year growth of approximately 12% without the impact of the shipping delays caused by Hurricane Milton. Total operating expenses were $40.2 million for the nine months ended September 30, 2024 compared with $42.3 million to the same period last year. Cost of revenues increased from the prior year to $13.3 million for the nine months ended September 30, 2024, compared to $12.1 million for the same period last year. Selling, general and administrative expenses decreased to $25.6 million compared to $29.9 million in the prior year. Specifically, this decrease entails $1.7 million in legal costs for the settlement with Biofrontera AG in April 2023, $1.3 million of non-personnel sales and marketing expenses due to a lower level of marketing activities in general, $0.6 million in general business administration, and $0.6 million in personnel expenses, partially offset by legal costs relating to the complaints filed by our competitor. Adjusted EBITDA was negative $13.9 million for the nine months ended September 30, 2024 compared with negative $15.8 million for the same period last year, primarily driven by the lower SG&A costs mentioned above. Conference Call Details Conference call: Thursday, November 14, 2024 at 10:00 AM Eastern Time Toll Free: 1-877-877-1275 (U.S. toll-free) International: 1-412-858-5202 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=OvxLI2Kz About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz \u00ae with the RhodoLED \u00ae lamp series for PDT of Actinic Keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers 2 . The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter . 1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/ Contacts Investor Relations Andrew Barwicki 1-516-662-9461 ir@bfri.com Forward-Looking Statements Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company\u2019s revenue guidance, business and marketing strategy, revenue growth, sales force productivity, growth strategy, liquidity and cash flow, potential to expand the label of Ameluz\u00ae, available market opportunities for Ameluz\u00ae, ongoing clinical trials, educational outreach efforts, and other statements that are not historical facts. The words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d, \u201ctarget\u201d, \u201cgoal\u201d, \u201cassume\u201d, \u201cwould\u201d, \u201ccould\u201d or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events; nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, our reliance on sales of products we license from other companies as our sole source of revenue; the success of our competitors in developing generic topical dermatological products that successfully compete with our licensed products; the success of our principal licensed product, Ameluz\u00ae; the ability of the Company\u2019s licensors to establish and maintain relationships with contract manufacturers that are able to supply the Company with enough of the licensed products to meet our demand; the ability of our licensors or their manufacturing partners to supply the licensed products that we market in sufficient quantities and at acceptable quality and cost levels, and to fully comply with current good manufacturing practice or other applicable manufacturing regulations; the ability of our licensors to successfully defend or enforce patents related to our licensed products; the availability of insurance coverage and medical expense reimbursement for our licensed products; the impact of legislative and regulatory changes; competition from other pharmaceutical and medical device companies and existing treatments, such as simple curettage and cryotherapy; the Company\u2019s ability to achieve and sustain profitability; the Company\u2019s ability to obtain additional financing as needed to implement its growth strategy; the Company\u2019s ability to retain and hire key personnel; and other factors that may be disclosed in the Company\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), which can be obtained on the SEC website at www.sec.gov . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management\u2019s current estimates, projections, expectations and beliefs. The Company does not undertake to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release, except as required by law. BIOFRONTERA INC. CONDENSED CONSOLIDATED BALANCE SHEETS ( In thousands, except par value and share amounts ) September 30, 2024 December 31, 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 2,873 $ 1,343 Investment, related party 8 78 Accounts receivable, net 4,874 5,162 Inventories, net 6,526 10,908 Prepaid expenses and other current assets 350 425 Assets held for sale 2,300 - Other assets, related party - 5,159 Total current assets 16,931 23,075 Property and equipment, net 82 134 Operating lease right-of-use assets 1,081 1,612 Intangible asset, net 39 2,629 Other assets 383 482 Total assets $ 18,516 $ 27,932 LIABILITIES AND STOCKHOLDERS\u2019 EQUITY Current liabilities: Accounts payable 2,027 3,308 Accounts payable, related parties 3,680 5,698 Operating lease liabilities 670 691 Accrued expenses and other current liabilities 4,655 4,487 Short term debt - 3,904 Total current liabilities 11,032 18,088 Long-term liabilities: Warrant liabilities 1,601 4,210 Operating lease liabilities, non-current 324 804 Other liabilities 29 37 Total liabilities 12,986 23,139 Commitments and contingencies Stockholders\u2019 equity: Series B Convertible Preferred stock, $0.001 par value, 20,000,000 shares authorized, no Series B-1, 4,695 Series B-2 and 7,093 Series B-3 shares issued and outstanding as of September 30, 2024 and no shares issued and outstanding as of December 31, 2023 - - Common stock, $0.001 par value, 35,000,000 shares authorized; 6,529,792 and 1,517,628 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 7 2 Additional paid-in capital 121,536 104,441 Accumulated deficit (116,013 ) (99,650 ) Total stockholders\u2019 equity 5,530 4,793 Total liabilities and stockholders\u2019 equity $ 18,516 $ 27,932 BIOFRONTERA INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ( In thousands, except per share amounts and number of shares ) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Product revenues, net $ 9,012 $ 8,879 $ 24,744 $ 23,423 Revenues, related party - 17 18 52 Total revenues, net 9,012 8,896 24,762 23,475 Operating expenses Cost of revenues, related party 4,801 4,495 12,839 11,814 Cost of revenues, other 76 95 496 262 Selling, general and administrative 8,425 8,619 25,589 29,874 Selling, general and administrative, related party 1 74 30 193 Research and development 669 33 1,306 44 Change in fair value of contingent consideration - 200 - 100 Total operating expenses 13,972 13,516 40,260 42,287 Loss from operations (4,960 ) (4,620 ) (15,498 ) (18,812 ) Other income (expense) Change in fair value of warrants (680 ) 598 1,329 2,001 Change in fair value of investment, related party (2 ) (2,212 ) (12 ) (6,635 ) Loss on debt extinguishment - - (316 ) - Interest income (expense), net 8 (142 ) (1,995 ) (256 ) Other income (expense), net (32 ) 35 154 65 Total other expense (706 ) (1,721 ) (840 ) (4,825 ) Loss before income taxes (5,666 ) (6,341 ) (16,338 ) (23,637 ) Income tax expense 3 1 25 20 Net loss $ (5,669 ) $ (6,342 ) $ (16,363 ) $ (23,657 ) Loss per common share: Basic and diluted $ (0.98 ) $ (4.64 ) $ (3.39 ) $ (17.57 ) Weighted-average common shares outstanding: Basic and diluted 5,773,993 1,366,842 4,833,091 1,346,264 BIOFRONTERA INC. GAAP TO NON-GAAP ADJUSTED EBITDA RECONCILIAITION ( In thousands, except per share amounts and number of shares ) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net loss $ (5,669 ) $ (6,342 ) $ (16,363 ) $ (23,657 ) Interest expense, net (8 ) 142 1,995 256 Income tax expenses 3 1 25 20 Depreciation and amortization 129 251 387 769 EBITDA (5,545 ) (5,948 ) (13,956 ) (22,612 ) Loss on debt extinguishment - - 316 - Change in fair value of contingent consideration - 200 - 100 Change in fair value of warrant liabilities 680 (598 ) (1,329 ) (2,001 ) Change in fair value of investment, related party 2 2,212 12 6,635 Legal settlement expenses - - - 1,225 Stock based compensation 288 207 720 817 Expensed issuance costs - - 354 - Adjusted EBITDA $ (4,575 ) $ (3,927 ) $ (13,883 ) $ (15,836 ) Adjusted EBITDA margin -50.8 % -44.1 % -56.1 % -67.5 % View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BFRI", "date": "2024-11-14T01:15:00", "sentiment": {"score": 0.8334992295131087, "confidence": 0.8488002419471741, "probabilities": {"positive": 0.8488002419471741, "negative": 0.015301012434065342, "neutral": 0.13589882850646973}}, "embedding": [-0.021682213991880417, -0.0964772030711174, -0.06431911885738373, -0.08371716737747192, 0.04682951420545578, -0.05709756910800934, -0.16769658029079437, 0.216386079788208, 0.06436637043952942, 0.09697423875331879, -0.02727781981229782, 0.03945292532444, 0.024583837017416954, 0.007314534392207861, -0.04333537071943283, 0.024940289556980133, 0.0017139092087745667, -0.08313514292240143, -0.0516209602355957, 0.049098338931798935, -0.020737387239933014, 0.05049985274672508, -0.05090183764696121, 0.04862905293703079, -0.02138897031545639, 0.09287592768669128, -0.21387116611003876, -0.054286763072013855, -0.12061931937932968, -0.06228887289762497, 0.11486189067363739, 0.08026229590177536, 0.005848202854394913, -0.12339827418327332, 0.025452379137277603, 0.0130064832046628, -0.10504839569330215, -0.02703111618757248, -0.09331539273262024, 0.08144162595272064, -0.05253588408231735, -0.09879657626152039, -0.09750248491764069, -0.07212229818105698, 0.01808077283203602, -0.1671992838382721, -0.07859369367361069, 0.06906085461378098, 0.11289821565151215, 0.044724952429533005, -0.12854483723640442, -0.10779691487550735, -0.10689990967512131, 0.04735643416643143, -0.04366440698504448, 0.003172490978613496, -0.03493881598114967, -0.057914067059755325, -0.02316173166036606, -0.011053425259888172, -0.0753384679555893, -0.006686381064355373, -0.07767549902200699, 0.007856007665395737, 0.12318213284015656, 0.05334901809692383, -0.1216605007648468, -0.06394361704587936, 0.046712614595890045, -0.00021334178745746613, 0.0955689549446106, -0.06894494593143463, 0.015009058639407158, -0.032377712428569794, -0.06972839683294296, 0.12683656811714172, 0.27509206533432007, 0.18942797183990479, 0.12884113192558289, -0.05153775215148926, 0.07193884253501892, 0.012503676116466522, 0.04442755877971649, -0.0840161144733429, -0.03546096757054329, 0.05548975616693497, 0.024810021743178368, 0.10613653063774109, 0.024087924510240555, 0.100751131772995, 0.16539078950881958, -0.009309054352343082, 0.03247528895735741, -0.018826521933078766, -0.0696326494216919, 0.001115771010518074, -0.05599973350763321, -0.13771691918373108, 0.07247377187013626, -0.0005247108638286591, 0.05768449604511261, -0.04494234174489975, -0.09933825582265854, -0.04893733933568001, -0.11898058652877808, -0.03523990884423256, 0.07591591775417328, 0.010295701213181019, -0.034867413341999054, 0.040731362998485565, -0.08918893337249756, 0.08080204576253891, -0.021076466888189316, -0.07077283412218094, -0.08249115943908691, 0.16993364691734314, -0.03881499171257019, -0.09692990034818649, 0.12985478341579437, -0.1097056120634079, 0.06006244942545891, 0.022945670410990715, 0.07512784004211426, -0.14519637823104858, 0.07501311600208282, 0.04053404927253723, -0.0750909298658371, 1.35030593608971e-32, 0.05993853136897087, -0.005501052364706993, 0.020807715132832527, 0.0033244946971535683, -0.0016219972167164087, 0.0680919885635376, -0.01613236591219902, 0.010488614439964294, 0.010340406559407711, -0.1121826097369194, -0.13306353986263275, 0.06447416543960571, -0.06898941099643707, 0.0023865385446697474, -0.06820232421159744, -0.15796998143196106, 0.0038436870090663433, 0.013373786583542824, -0.13018706440925598, -0.015695730224251747, -0.012894096784293652, -0.07280895859003067, -0.03218859061598778, 0.06040392071008682, 0.05260531231760979, 0.0582551583647728, -0.1000247597694397, 0.10389675199985504, -0.06169923394918442, 0.06727475672960281, -0.007423629984259605, 0.030337130650877953, -0.008701617829501629, -0.054820746183395386, -0.12866073846817017, -0.061772365123033524, -0.13473160564899445, -0.14320489764213562, 0.06031780689954758, 0.054195620119571686, -0.05133165791630745, 0.17597004771232605, -0.05799390375614166, 0.03358788415789604, 0.09608921408653259, -0.0003620297648012638, -0.022743551060557365, 0.042362939566373825, 0.05353332683444023, -0.009846039116382599, -0.04660114645957947, 0.01954660937190056, -0.04594676196575165, -0.07648521661758423, -0.07495839148759842, 0.027703413739800453, -0.06600072234869003, -0.11071557551622391, 0.08965031802654266, 0.07389019429683685, 0.023628702387213707, 0.09629344940185547, 0.03435919061303139, 0.010118834674358368, -0.07836738228797913, 0.05856149643659592, 0.15347090363502502, 0.13661964237689972, -0.018361546099185944, 0.06536766141653061, -0.025566697120666504, -0.059290867298841476, 0.207153782248497, 0.0018559722229838371, 0.18196141719818115, -0.051869139075279236, 0.09146933257579803, 0.1260242611169815, 0.0009654499590396881, 0.015399754047393799, -0.008044084534049034, 0.05521959066390991, 0.08198808878660202, 0.07701455801725388, 0.050042517483234406, 0.037721410393714905, 0.02809351310133934, 0.03811841458082199, -0.13771413266658783, -0.011874819174408913, 0.09913021326065063, -0.02462289109826088, -0.01483909785747528, 0.18077966570854187, -0.06251692026853561, -1.2763788024929087e-32, -0.02692803367972374, 0.07575458288192749, 0.0242141205817461, -0.10210070013999939, -0.00893337745219469, 0.09124626219272614, 0.11466632038354874, -0.03582500293850899, 0.03471555933356285, -0.11671039462089539, -0.06360779702663422, 0.15865476429462433, -0.024863235652446747, -0.11844703555107117, 0.002000105567276478, 0.01188287790864706, 0.015777504071593285, -0.13674329221248627, -0.1713329404592514, -0.0008925497531890869, -0.0073854876682162285, 0.11813504993915558, -0.06456518173217773, -0.007443170994520187, -0.0345463752746582, 0.03370155394077301, 0.027638889849185944, 0.06798259168863297, 0.04976992309093475, -0.11453312635421753, 0.001224081963300705, 0.045967258512973785, -0.23596885800361633, 0.03636381775140762, 0.0162203311920166, 0.016279837116599083, 0.04348646104335785, -0.0959516391158104, -0.03821860998868942, -0.10914140939712524, 0.1731874942779541, 0.0642533153295517, -0.021596495062112808, 0.002402159385383129, 0.034732017666101456, 0.00307655893266201, 0.027313392609357834, -0.11560491472482681, 0.17719775438308716, 0.07047560065984726, -0.07270711660385132, -0.04928124323487282, -0.04056724160909653, 0.16484391689300537, 0.03465729206800461, -0.04031314328312874, 0.13489890098571777, -0.04018368571996689, -0.14035697281360626, 0.06359532475471497, 0.026477470993995667, 0.0668884664773941, 0.0749235525727272, -0.02679397538304329, 0.13394957780838013, 0.10297155380249023, 0.1484401971101761, 0.007439363747835159, 0.07630889862775803, -0.0028856610879302025, 0.015453692525625229, 0.0029031054582446814, 0.03860842436552048, -0.02887285128235817, 0.02125050500035286, 0.1114238053560257, -0.06213663890957832, -0.16300100088119507, -0.16482239961624146, -0.011030576191842556, -0.02147120237350464, -0.04083362966775894, -0.029618458822369576, -0.021551089361310005, -0.008960532024502754, 0.009633517824113369, 0.06902967393398285, -0.14284807443618774, -0.04892217367887497, 0.07252110540866852, -0.0780387818813324, -0.00753367692232132, -0.053065225481987, 0.09527920186519623, 0.10192674398422241, -1.0058724342343339e-07, 0.06413950026035309, 0.01203523762524128, 0.04013501852750778, 0.005600113421678543, 0.11073548346757889, -0.10911490023136139, -0.02177637256681919, 0.08323803544044495, -0.01022131647914648, 0.10923521220684052, 0.021634913980960846, 0.15054678916931152, -0.01708107441663742, -0.027289075776934624, -0.09611815959215164, -0.0007747176568955183, -0.08231394737958908, -0.03696087375283241, -0.057428546249866486, -0.11311278492212296, -0.0865420401096344, 0.0325743705034256, -0.020137561485171318, -0.12538941204547882, 0.09895988553762436, -0.10646241903305054, 0.015533318743109703, 0.12234147638082504, 0.061937715858221054, -0.10437586903572083, -0.003433497855439782, -0.014488648623228073, 0.017795924097299576, -0.029838241636753082, -0.04781462997198105, -0.138845294713974, 0.07767805457115173, 0.07967666536569595, 0.013123204931616783, 0.10821429640054703, 0.0973561480641365, -0.03596201539039612, 0.007199199870228767, 0.05331535264849663, -0.02249854989349842, -0.025342557579278946, -0.2179448902606964, 0.053448136895895004, 0.02275678515434265, -0.15461347997188568, 0.10097844898700714, -0.02905244752764702, 0.018847238272428513, -0.037530601024627686, -0.04670488461852074, -0.019965481013059616, -0.09687197953462601, -0.0086335064843297, 0.01275921892374754, -0.024319246411323547, 0.020767029374837875, -0.24712035059928894, 0.08210425078868866, 0.07549723982810974], "changes": {"1wk": -6.36254893501956, "1mo": 27.25089283535716}}]